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Pleuromutilin and its semisynthetic derivatives show great potential as antibiotics for human 
use, however production from its natural fungal source gives a relatively low yield. For 
further development of this drug, an efficient approach for enhancing the production of 
pleuromutilin is needed. Heterologous expression is a promising approach that allows transfer 
and expression of the entire pleuromutilin biosynthetic pathway in new hosts. This strategy 
could solve the limitation of low yield and also may allow the modification of the pathway to 
make novel products in these new hosts. 
Initially Aspergillus oryzae was used for heterologous expression of the pleuromutilin 
biosynthesis pathway. In an attempt to increase flux through the pathway, the pdc promoter 
was chosen to replace the weak eno promoter. The pdc promoter could effectively drive the 
GFP gene in A. oryzae, however transformants containing biosynthetic genes under control 
of the pdc promoter did not show any improvement in accumulation of the desired 
metabolites and the reasons for this are still unclear. Plant-based production systems may 
provide an alternative to filamentous fungi, so Nicotiana tabacum was explored as a 
heterologous host. Using the Golden Gate assembly method, expression vectors were 
developed to express part or all of the seven gene pleuromutilin biosynthesis pathway. 
Through transient Agrobacterium infiltration of leaves, it was demonstrated that candidate 
pleuromutilin intermediates were likely being produced, however this was correlated with 
chlorosis in the leaf tissues suggesting a toxic effect in planta, limiting this direction of 
research. Given others have had success using yeast-based expression systems for terpene 
products, this was also employed as a platform for the heterologous expression of 
pleuromutilin biosynthesis genes. The pathway-specific GGS and Cyclase were expressed 
under regulation of the GAL promoters and a product consistent with the initial pleuromutilin 
precursor was detected, however GAL-based induction was not reliable and unexpectedly, 
yields were not enhanced in the yeast host AH109 which ought to give elevated titres for 
diterpene products.  
Whilst all three host systems proved to be amenable to manipulation, in all cases, further 
optimisation of gene expression is required in order to obtain the desired levels of enzyme 
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Chapter 1 Introduction 
 
1.1 Antibiotics 
Antibiotics refer to a group of drugs that have the ability to prevent and treat bacterial 
infection. Unfortunately, the overuse and misuse of these medicines led to the rapid 
emergence of resistant bacteria around the world (O’Neill, 2015). This crisis results in a high 
mortality rate of patients and a great economic burden on the health care system worldwide. 
This situation also reflects the lack of development for new antibiotics. To overcome this 
problem, research efforts to discover and develop a new antibacterial agent are urgently 
needed.  
 
1.1.1 History of antibiotic from its natural source 
The majority of the antibiotic drugs that are available in the market originally came from 
natural sources such as bacteria, fungi and plants. The treatment of infections started several 
thousand years ago long before people realized that the infections were caused by bacteria. In 
the pre-antibiotic era, the evidence that fungal and plant extracts were used to treat infections 
were well-documented in writing from ancient Egypt, Greece, and China. One of the 
successful treatments was the topical application of filamentous fungi grown on bread to treat 
infected wounds from the ancient Egyptians (Cowan, 1999, Ventola, 2015). The utilization of 
this mould benefit continued for many years and was referenced and published in the book 
called Theatrum Botanicum by John Parkinson in 1640 (Gould, 2016). Another well-known 
example is qinghaosu (later known as artemisinin), an anti-malaria drug which was extracted 
from the leaves of Artemisia annua plant and used by Chinese herbalists in their traditional 
Chinese medicine (TCM) as a remedy for many illnesses for thousands of years (Aminov, 
2010, Gould, 2016). Moreover, traces of tetracycline have been detected in the bones of the 
ancient Sudanese Nubian population and the late Roman period during occupation of Egypt 
hinting at its use, although the origin of the tetracycline is still unknown (Cook et al., 1989). 
The modern era of antibiotics came into being with two famous researchers, Paul Ehrlich and 
Alexander Fleming, who reported a breakthrough of antibiotic discovery to the world. In the 
late 19th century Paul Ehrlich observed the action of a chemical dye that could stain some 
bacteria but not the others. He hypothesized that there was a possibility to create a compound 
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that could selectively kill specific bacteria without being harmful to the others or to the host. 
Ehrlich’s idea of a “magic-bullet” came along with a large scale and systematic screening 
program in 1904 (Aminov, 2010). He conducted lab work together with the chemist Alfred 
Bertheim and the bacteriologist Sahachiro Hata, to discover a drug that could treat syphilis, a 
sexually-transmitted disease that was widespread and incurable at that time, caused by 
Treponema pallidium. During that time syphilis was treated with inorganic mercury salts but 
the poor results came together with serious side effects. According to their project, hundreds 
of organoarsenic derivatives of a highly toxic drug Atoxyl were synthesised and tested 
against rabbits infected by syphilis. Within the 600th series of tested compounds, the 
compound number 606 showed a strong result, curing infected rabbits and further study of 
this compound on humans also showed a promising result of treatment by IV injection 
(Ehrlich and Hata, 1910). In 1909, Salvarsan, the arsenic-based compound which was proved 
to cure syphilis efficiently, was launched into the market. This drug could be called the first 
synthetic antibiotic of the modern world (Gould, 2016).  
The systematic screening approach by Paul Ehrlich became a standard method in the 
pharmaceutical industry as a strategy to search for new drugs. Thousands of drugs were 
synthesised and screened in clinical trials for antibiotic properties. As a result, a sulfa 
(sulphonamide) drug named Prontosil, was synthesized by Josef Klarer and Fritz Mietzsch in 
1932. Its antibiotic activity was tested and it proved to be active against streptococcal 
infection (Domagk, 1935). Subsequently, a later study demonstrated that Prontosil had no 
direct antibiotic activity (Welch, 1937). It was claimed to be a prodrug of the sulfa drug. 
However, the mass production of Prontosil and its derivatives had already been done by 
many companies, due to its cheap production cost, ease of modification and being off-patent. 
This phenomenon contributed to one of the most widely disseminated drug resistance cases in 
the world, the sulfa drug resistance (Aminov, 2010). 
The discovery of Penicillin (Figure 1) by Alexander Fleming in 1928 is probably the most 
well-known case for the discovery of an antibiotic. Penicillin was found after an observation 
made by Fleming of a Staphylococcus bacteria plate he accidentally left on the bench, that 
had become contaminated by a fungus, Penicillium notatum (Durand et al., 2019). He noticed 
that there was a clear zone free of bacteria, wherever the fungus grew on the plate. So, he 
concluded that the fungus might secrete a substance which has the ability to kill bacteria. 
Unfortunately, even after 12 years following this observation, Fleming still faced a problem 
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with the purification of the active compound from fungal culture. In 1939, Howard Florey 
and Ernst Chain, together with their team, resolved this issue and successfully worked on the 
extraction of the fungal culture and obtained the pure compound, which they named as 
penicillin. The drug had a potent antibiotic activity, largely against Gram-positive bacteria 









Figure 1 Penicillin structure. 
 
Even though there were a number of synthetic antibiotics which were discovered and isolated 
prior to penicillin, it was penicillin that made its way to become successful as the first mass 
produced antibiotic in the world, being used to save many lives of soldiers during the World 
War II (Gould, 2016, Nicolaou and Rigol, 2018). After the breakthrough of penicillin, many 
more antibiotics were discovered and isolated, especially during 1950s to1970s which has 
since become known as the golden age of the discovery of antibiotics. 
The pioneer in the discovery of antibiotics in this era was Selman Waksman, an American 
biochemist. Unlike Fleming who discovered penicillin by accident, Waksman developed a 
novel systematic way to screen bacteria for the antibiotic activity known as the “Waksman 
platform”. The basic principles for his screening methods were based on the observation of 
the growth inhibition zones of the tested strain (strain that was suspected to produce an 
antibiotic) over the indicator strain (targeted strain). There are three main methods to test on 
an agar plate; the cross-streak, the spot on the lawn and the well diffusion (see Figure 2) 
(Durand et al., 2019). These platforms had advantages over the animal screening model by 
being faster and using less resources, so became widely used for a mass screening of 
expected antibiotic-producing organisms. Both academics and industry were inspired by the 
Waksman platform and led to many new classes of antibiotics during the golden era of 


















Figure 2 Illustrates the three methods from Waksman platforms; 1) the cross-streak method: 
by streaking the test strain vertically on agar plate and incubating until it reaches its 
exponential phase, then a horizontal streak of indicator strain is made, and the plate is 
incubated again and the inhibition zone is monitored. 2) the spot on the lawn method: 
screening process is done by adding a single drop of the test strain on a lawn of indicator 
strain on an agar plate, then after incubation the inhibition zone is observed and 3) the well 
diffusion method: based on the diffusion of liquid broth or the supernatant of the test strain 
through an agar plate which is covered with a lawn of an indicator strain and then the clearing 
zone is measured. (sourced from (Durand et al., 2019). 
By using his own screening platform, Waksman successfully discovered around twenty new 
antibiotics which mostly came from the Actinomycetes, such as streptomycin, neomycin and 
actinomycin. Streptomycin, an antibiotic produced by the soil organism Streptomyces 
griseus, was discovered by the initial systemic screening of soil bacteria by Waksman and his 
team in 1944. It was the first antibiotic which was developed after penicillin and was 
effective in treating tuberculosis (Durand et al., 2019). After the kick-start of streptomycin 
and successful screening methods from Waksman, many research efforts were made 
 5 
screening other organisms for the production of antibiotics, but the results were very limited. 
In 1952, the pharmaceutical company Eli Lilly asked for help from missionaries to send soil 
samples from various exotic locations for the screening of new antibiotics. Vancomycin was 
then discovered from Amycolatopsis orientalis, a soil sample sent from the jungle in Borneo. 
It was indicated for use in the treatment of penicillin-resistant Staphylococcus aureus. Due to 
the fast development of penicillin-resistance by staphylococci, the drug was given fast track 
approval by the FDA and launched into the market under the trade name Vascocin in 1958 
(Gould, 2016). However, it was not used as a first line drug, because it had to be given by IV 
and was later found have toxic effects to ears and kidney. Soon after, a less toxic drug, 
methicillin was developed and used to treat penicillin-resistant Staphylococcus aureus. 
Methicillin, the first -lactamase-resistant semi-synthetic penicillin was subsequently 
developed by Beechams in 1959. But in 1961, only two years after the discovery of 
methicillin, the first report of S. aureus strain resistance to methicillin occurred in United 
Kingdom and was so called the birth of Methicillin-resistant Staphylococcus aureus (MRSA). 
This soon spread internationally to other European countries and later to Japan, Australia and 
the United States (Enright et al., 2002). The emergence of methicillin resistant strains caused 
a sharp increase in hospital acquired infections. MRSA isolates also often showed resistance 
to other -lactams drugs or to the entire class of penicillin-like antibiotics including 
penicillin, amoxicillin, methicillin etc. The actual origin of MRSA is still poorly understood. 
Many studies have been conducted to characterise and identify the relatedness of MRSA 
isolates from individual hospitals or countries, but no correlation has been found and that 
makes it more difficult to combat this resistant disease (Hussain et al., 2000).  
Aside from the focus on the screening of new organisms for antibiotic production, there is a 
question of how the growth conditions affect the production of secondary metabolites. Thus, 
a hypothesis arose based on growing a strain under several different conditions that might 
lead to a higher yield or production of new antibiotic compounds (Hewage et al., 2014). This 
issue has been noticed since the early days of the development of penicillin for the industrial 




Microorganisms usually contain various cryptic biosynthetic gene clusters, which are not 
related to characterized molecule of any secondary metabolites. These biosynthetic gene 
clusters are thought to be silent, which refer to the gene clusters that are unable to express 
under normal laboratory conditions. The strategy of one strain many compounds 
(OSMAC) has been developed and shown as an efficient tool that can activate many silent 
gene clusters. The concept of this cultivation-based approaches is aimed to investigate how a 
single strain can produce different secondary metabolites when grown under different culture 
conditions such as medium composition, temperature, aeration or the addition of chemical 
elicitors (Bode et al., 2002, Romano et al., 2018). The study by Bode et al., (2002) 
demonstrated that the fungus Aspergillus ochraceus, which was known to produce only the 
main metabolite aspinonene, was able to produce 15 additional metabolites after changing 
cultivation parameters such as temperature, salinity, aeration, and even the shape of the 
flasks.  
Another support from the study of the genome of two Streptomyces species; S. coelicolor and 
S. avermitilis (Bentley et al., 2002, Ikeda et al., 2003). The result from both cases showed that 
the genome of the bacteria contains the genes involved in the response of external stimuli, 
various stress conditions and the variety of nutrient sources. Due to lack of knowledge of the 
enzymes activities within the pathway, lead to the problem of how to stimulate the full 
function of the metabolic potential of the microorganisms under the laboratory conditions and 
then no new drugs were discovered. In addition, the general strategy was done by assigning a 
different growth condition with random factors, resulted in the production of known 
compounds or useless metabolites with lacking a desired antibiotic property. In order to solve 
this problem,  further investigation of the genomics, bioinformatics and microbial physiology 








1.1.2 Chemical synthesis and semi-synthetic of antibiotic 
Since the 1970s, the discovery rate of novel antibiotics declined then completely stalled. This 
coincided with widespread use of antibiotics, caused a rapid growing resistance problem. 
With few, if any, new compounds in the discovery pipeline, focus moved towards a 
modification strategy of the existing core structures, the so called semi-synthetic route. The 
objectives of this strategy were to enhance the antibiotic activity, broaden the spectrum of 
activity and minimize or overcome any resistance mechanisms, alongside reduced human 
toxicity (Aminov, 2010).  
Typically, each group of antibiotics shares the same core structure or scaffold. During the 
semi-synthetic procedure, the core structure is maintained because this is usually responsible 
for molecule connectivity and key structure-activity relationships (SAR). In order to improve 
pharmaceutical properties of the drug, new chemical groups may be introduced into the 
periphery of the molecule (Fischbach and Walsh, 2009). For example, Erythromycin was first 
of the Macrolide group, discovered from soil samples. It is a metabolite of 
Saccharopolyspora erythraea. Due to low yields and structurally complexity of the 
erythromycin molecule, a total synthesis was unrealistic, so the second generation such as 
clarithromycin were developed via a semisynthetic route and this contains a methoxy group 
at the C6 position of the lactone ring (Figure 3). As a result, clarithromycin has improved 
acid stability when compared to the first-generation macrolide, erythromycin. When the 
macrolide resistance emerged, telithromycin, a ketolide and a third-generation macrolide was 
developed. Ketolide is an erythromycin derivative characterized by replacing the cladinose 
sugar with keto-group at C3 and introducing carbamate extension into the lactone macrocycle 
at C11/C12. The modification to telithromycin demonstrated a greater binding affinity of the 
drug to its target site, and also improved its microbiological properties to be active against the 


























Figure 3 The development of next generation antibiotics through a chemical modification of 
their original scaffolds. Source from (Fischbach and Walsh, 2009). 
 
This strategy for improving the existing scaffolds was very successful and has continued to 
provide new effective antibiotics for the market but very few truly new antibiotics have been 
developed in the last twenty years. It has highlighted that resistance to each new variant does 
occur, sometimes very rapidly, and shows that there is an ongoing challenge to continue to 











1.1.3 The antibiotic resistance crisis 
Antibiotic resistance refers to the ability of bacteria to resist the action of the antibiotic that 
targets them (Blair et al., 2015). During the evolution of resistance, bacteria can acquire a 
pre-existing resistance gene via other bacteria or from DNA in the environment. It is also 
reported that exposure to sub-lethal doses of antibiotic can result in selection of mutations in 
bacteria, resulting in increased resistance to the drug through modifications to outer 
membranes or other mechanisms that result in reduced permeability to the drug (Munita and 
Arias, 2016). 
There are three major groups of mechanisms that can describe this action. Firstly, limiting the 
entry of the antibiotic by reducing permeability of cell membrane, or increasing action of the 
efflux transporters will cause a poor penetration and minimize the intracellular concentration 
of antibiotic in the bacteria cell. Secondly, mutation of the target site can alter the efficiency 
of drug-binding so reducing the drugs effect. Thirdly, the bacteria may produce an enzyme 
that can make changes to the antibiotic molecule. Such a direct modification of the antibiotic 
structure may result in the antibiotic losing its ability before it reaches the target site (Blair et 
al., 2015). 
Antibiotic or antimicrobial resistance (AMR) was named as one of the top three global health 
crises of the 21st century by the World Health Organization (WHO) (WHO, 2015). A rapid 
emergence of AMR is leading to greater effects in terms of morbidity, mortality and economy 
impact for any population and government worldwide. The Centres for Disease Control and 
Prevention (CDC) provided a report showing that in the United States more than 2 million 
people are affected by organisms that are resistant to antibiotics each year and at least 23,000 
died. In European countries, according to a current report, 25,000 people died as a result of 
infection by an antibiotic-resistant organism annually (CDC, 2019). Moreover, the report also 
highlighted a significant increase in mortality caused by what were regarded as comparatively 
manageable diseases such as Klebsiella pneumoniae within the European populations during 
the past four years. Some predictions are that the number of such deaths globally will reach 
nearly 300 million by 2050 and it is estimated that the global economic loss of up to $100 
trillion is caused by antibiotic resistance (O’Neill, 2015).  
There are several factors that have made the antibiotic resistance problem become worse. The 
biggest cause is the overuse of antibiotics. In some countries, antibiotics are an over the 
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counter drug, which patients can easily access without a prescription. Studies showed a 
statistically significant correlation between the increase consumption of antibiotics and the 
increase of antibiotic resistance (Goossens et al., 2005, Baquero et al., 2002). Another major 
issue is a lack of new antibiotics launched in the market. A lack of economic appeal due to a 
low cost of antibiotic when compared with the drugs for treatment of chronic diseases, has 
led many pharmaceutical companies to give up on antibiotic development. Besides this, the 
difficulties in pursuing regulatory approval are always an obstacle and may have led to the 
reduction in the number of new antibiotics in the market (Ventola, 2015).  
 
1.1.4 A current approach for treating bacterial infection  
After the golden age of antibiotics, most pharmaceutical companies have reduced their efforts 
in the discovery and development of antibiotics or completely withdrawn from this process. 
Antibiotic discovery is a time-consuming process of screening and charactering for active 
compound and gives a poor return on investment compared to development of other drugs 
(Durand et al., 2019). A traditional strategy for natural compound discovery is defined as a 
top-down process. It starts with finding and collecting specimens from diverse environments. 
This is followed by cultivating under laboratory conditions, extraction and then antibiotic 
activity screening and characterizing for a desired compound. All these techniques use a 
complicated system to elucidate new active compounds without any knowledge involved in 
the biosynthesis and often result in re-isolation of known compounds (Luo et al., 2014). As a 
result, there is a big gap in the antibiotic pipeline to release a new drug.  
In contrast, the bottom-up approach for novel natural product discovery has focussed on 
genome sequence data. This uses various gene manipulation methods to identify the genes 
and enzymes involved in the biosynthesis pathway of interest. These approaches have 
provided a powerful strategy to uncover  hidden gene clusters from microorganisms and may 
allow the production of a metabolite from normally silent gene clusters in the host organisms 
that may have the potential to be a new antibiotic drug (Luo et al., 2014). Several bottom-up 






1.1.4.1 Genome mining approach 
Genome mining is a revolutionary approach of the procedure to discover secondary 
metabolites from natural sources. It refers to the process of finding a potential secondary 
metabolite based on genome sequence information (Bachmann et al., 2014, Choi et al., 2018). 
There are many bioinformatic tools available and widely used for mining procedure such as 
BLAST, HMMer, BAGEL, PRISM and anti-SMASH. These tools are employed for selecting 
a target biosynthetic gene cluster for two main purposes. Firstly, to identify core genes from 
the known scaffolds. This strategy (Figure 4) based upon the homology comparison with the 
known secondary metabolite gene clusters, from the conserved motifs for each pathway type; 
polyketides synthetase PKS, nonribosomal peptide synthetase (NRPS) or ribosomally 
synthesized and post-translationally modified peptides (RiPP). A new metabolite with any 
small novel variation in its structure may cause a significant change of the biological activity 
of product (Durand et al., 2019, Ward and Allenby, 2018). 
Secondly comes identifying tailoring enzyme genes within the target biosynthetic gene 
cluster, that are responsible for modification of the core structure and that may also have an 
impact on its biological activity. The method is more challenging in terms of defining the 
extent for the whole biosynthetic gene cluster (Choi et al., 2018, Ward and Allenby, 2018). 
However, the major problem of genome mining approach for discovery of new antibiotics is 
that this approach usually requires for the expression of  the whole biosynthetic gene cluster 



















Figure 4 A typical genome mining scheme. Microbial genome data obtained from genome 
sequencing using a next generation genome sequencer, followed by phylogenetic analysis of 
a targeted biosynthetic gene cluster using bioinformatic tools such as anti-SMASH. Then 
each cluster will be analyzed for its function. After the selection of a putative biosynthetic 
gene cluster some methods will be provided in order to awake a silent gene cluster. Finally, a 
potential product is uncovered. Source from (Choi et al., 2018). 
 
 1.1.4.2 Biological gene cluster activation approach 
The cluster activation/stimulation approach was developed in order to solve some difficulties 
that arise from genome mining. Under typical laboratory conditions many biosynthetic gene 
clusters are silent or barely expressed so their products would not be readily apparent. 
Therefore various stimulating approaches such as optimization of regulatory network, use of 
chemical elicitors, co-cultivation and heterologous expression have been developed in order 
to awake some sleeping biosynthetic gene clusters and drive that cluster from genome mining 
into reality (Choi et al., 2018).  
For example, the optimization of regulatory networks using a strong promoter to activate a 
gene cluster was successfully applied to Large ATP binding of the LuxR (LAL) pathway-
specific regulator, a silent type I polyketide biosynthetic gene cluster of Streptomyces 
ambofaciens (Laureti et al., 2011). The overexpression of LAL under the control of a strong 
constitutive ermE* promoter, resulted in the production of stambomycins A-D, four 
glycosylated macrolides as a product from the gene cluster. Another example comes from a 
chemical elicitor method, which showed that addition of atenolol in liquid culture of 
Streptomyces hiroshimensis led to the discovery of two novel antibiotics, taylorflavin A and 
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taylorflavin B (Moon et al., 2019). The most widely applicable method for biosynthetic gene 
cluster stimulating is heterologous expression, the concept is to clone a target cluster and 
transform it into a host in a way that guarantees its expression. The principal of this method 
will be discussed later in the section 1.3. 
 
1.1.5 A metabolic model for a yield improvement - the penicillin case study  
The process of penicillin discovery, the subsequent strain improvement and its large-scale 
production was a great breakthrough both for the pharmaceutical industry and for the therapy 
of infectious diseases (Ligon, 2004). 
The study published by Raper et al., (1944), reported the screening of related fungal isolates 
mostly from P. notatum and P. chrysogenum for the production of penicillin on agar plates. 
However, they noted that the area of inhibition zone and the production of penicillin were not 
directly related. Later, Moyer and Coghill (1946) reported that the production of penicillin 
from the isolate of P. chrysogenum was more suitable than Fleming’s original P. notatum. 
Initially, Moyer and Coghill (1946) could successfully increase the production of penicillin 
by focusing on the culturing conditions of the fungus in liquid culture. They found that using 
lactose as a carbon source, as well as the supplement of corn steep liquor into the 
fermentation medium could lead to a ten-fold increase of penicillin production.  
Besides the screening of strains and the optimization of culturing conditions, a random 
mutagenesis and consequent screening was employed to generate new mutant strains. This 
approach was widely used for strain improvement for industrial scale production. The theory 
is based on the exposure of the desired strains, which were already known to provide a high 
titre for the production of penicillin, with concentrated chemical agents such as nitroso-
methyl guanidine or strong physical agents like X-ray or UV radiation. This caused random 
genetic mutations in the treated strains and was then followed by screening for increased titre 
(Rowlands, 1984). In the case of P. chrysogenum NRRL 1951 (wild type) that was treated 
with X-ray, this provided the X-1621 mutant strain which increased the yield up to 300 
g/mL of penicillin. The Q-176 strain was then obtained from several rounds of classical 
mutagenesis and produced up to 550 g/mL of penicillin (Jami et al., 2010). The Q-176 strain 
was also known as the ancestor of the Wisconsin mutant strains; as named Wis 54-1255, 
which is a laboratory model strain. The Wis 54-1255 strain then generated many lines of high 
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producer mutant strains for penicillin included the overproducer mutant strains that are 
currently used for the industrial production of penicillin, which could yield up to 50,000 
g/mL in fed batch culture (Jami et al., 2010). Subsequent analysis of the mutant strains 
generated through consecutive rounds of mutagenesis showed that this approach led to the 
duplication of the gene cluster of penicillin biosynthesis. Although there was a direct 
correlation between increased copy number and the increase of titre of penicillin, a plateau 
effect occurred when the copy number of gene cluster reached 5 copies (Newbert et al., 
1997). This suggests that there might be other limiting factors that affect the titre of antibiotic 
production for instance changes to the other primary or secondary pathways within the same 
strain could alter the rate limiting precursor of penicillin (Newbert et al., 1997). 
Proteome studies (Jami et al., 2010) were conducted to observe and compare the cytosolic-
proteomes of three penicillin producing strains; P. chrysogenum NRRL 1951 (wild type 
strain), P. chrysogenum Wisconsin 54-1255 (a moderate penicillin mutant strain) and P. 
chrysogenum AS-P-78 (a high producer mutant strain). Among the three different strains, the 
improved high-producer AS-P-78 strain contains five to six copies of the penicillin 
biosynthesis gene cluster agreeing with the previous report from (Newbert et al., 1997). In 
addition, this strain also contains abundant microbodies, the organelles involved in the final 
step of penicillin pathway, when compared to the other strains. The result also showed that 
only the wild type strain contains a protein involved in pigment formation. Overrepresented 
proteins involved in secondary metabolism pathways of terpenoids and porphyrins were also 
found in the wild type, while the improved strains contain the lower amount of such proteins 
involved in other secondary metabolite pathways. Hence, it could be hypothesised that a very 
low penicillin yield of the wild type resulted from the interference of the other secondary 
pathways which could decrease the metabolic flux through the penicillin biosynthesis 
pathway. The overexpression of cysteine synthase, the enzyme that converts serine to 
cysteine, an amino acid essential to penicillin biosynthesis pathway, was detected in the Wis 
54-1255 strain when compared to wild type. The high producer strain AS-P-78 also contains 
a high level of cysteine synthase with additional increase in level of cystathionine -synthase, 
the enzyme that converts methionine to cysteine. This proved that the high producer strain 
AS-P-78 over-expresses two cysteine biosynthesis pathway genes which could increase flux 
through the penicillin pathway compared to the other two strains. Finally, the results from the 
high producer strain AS-P-78 also indicated a high level of protein involved in the formation 
of NADPH, the redox cofactor required for the biosynthesis of cysteine. With the increase in 
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cysteine biosynthesis of the high producer strain AS-P-78, this may in part explain why this 
strain provides the highest yield of penicillin among the three strains (Jami et al., 2010).  
The effective enhancing of penicillin production is an excellent example of how the low titre 
fungal secondary metabolite can be increased. The results from the intensive work on 
penicillin production have pointed out several factors to improve the yield of the antibiotic. 
Small increase in titre by the addition of copy number, but much of the increase is likely to be 
blocking or reducing the divert of metabolic flux cause by the other secondary metabolite 
pathways. The development of penicillin can also be a guideline to suggest the possibility for 
the improvement in the production of pleuromutilin from its natural source, Clitopilus 
passeckerianus, the basidiomycete fungus which is the main goal of this PhD thesis.  
Generally speaking, when considering the time and cost for the development of a new drug 
starting from the basic research study from its natural source until it make its way to the mass 
production and then to market, the whole process will have taken around 12 years or more 
(Figure 5) with the investment cost around £1.15 billion (DiMasi et al., 2010). Previous 
studies showed that for every 10,000-25,000 compounds that are screened and studied in the 
laboratory, only around 250 make it to the preclinical trial stage and then 5 might make their 
way to the clinical trial in humans, then finally perhaps only one can get approved by FDA 
and released into the market (Torjesen, 2015). This points out that a large number of 
candidate agents with reasonable yield will need to be discovered and produced before 
finding a likely usable product. Hence, it is worth looking for an alternative approach in order 
to shorten the time and also improve the yield for the production of a new drug. Heterologous 
expression systems should be considered as an option to address the limitation of the desired 
organism that has difficulty growing or is unable to grow under normal laboratory conditions. 
The use of heterologous expression in a new host system may help to solve the issue of the 
very low to non-existant expression of the genes within the biosynthetic pathway in the native 
host and then the improvement and scalable production for a desired secondary metabolite 



















Figure 5 This shows the stages involved in the development of new drugs and the 























1.2.1 Development of pleuromutilin and its derivatives  
With no new antibiotics being discovered, there has been an interest in revisiting compounds 
that were discovered during the golden age of antibiotics but that were not further developed 
at that time; one such compound is pleuromutilin. Pleuromutilin (Figure 6) was discovered 
and isolated in a crystalline form from two species of Basidiomycete fungi, Pleurotus mutilus 
(now, Clitopilus scyphoides) and P. passeckerianus (now, Clitopilus passeckerianus), by 
(Kavanagh et al., 1951). Pleuromutilin is a tricyclic diterpenoid antibiotic with antibacterial 
activities against Gram-positive pathogens and mycoplasma (Ling et al., 2014). In the 1960s, 
the structure of this antibiotic was elucidated and reported by both Arigoni's group (Arigoni, 
1962) and Birch's group (Birch et al., 1966) as a rather rigid 5-6-8 tricyclic carbon skeleton 









Figure 6 Pleuromutilin. 
 
Previous studies have shown that this antibiotic has a unique mode of action, which involves 
inhibition of protein synthesis by selectively binding to the peptidyl transferase centre of the 
50S bacterial ribosome subunit but has no effect on eukaryotic protein synthesis and does not 
bind to the mammalian ribosome (Hirokawa et al., 2008, Poulsen et al., 2001). Thus, cross-
resistance to other marketed antibacterial agents rarely occurs. The novel mode of action of 
pleuromutilin made it an attractive target in the development of novel antibiotics for the 
treatment of multi-drug resistant bacterial infections (Liu et al., 2015). 
Since the 1960s, extensive effort has been made to develop new pleuromutilin derivatives 
(Figure 7) with more potent antibacterial activity for human use (Ling et al., 2014). As a 
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result, two compounds have been successfully developed, but both of them were used as 
therapeutic agents for veterinary purposes. Tiamulin, the first practical pleuromutilin 
derivative, was used as a prophylactic and therapeutic agent against anaerobic bacteria, 
intestinal spirochetes and Mycoplasma spp. in swine and poultry (Xu et al., 2009). While, 
Valnemulin was approved in 1999 by the European Union and was used in treatment of 
enzootic pneumonia of pigs (Drews et al., 1975). Although both Tiamulin and Valnemulin 
were successfully applied in veterinary medicine, due to their rapid metabolism they were not 
suitable for human use. From then on, several other semisynthetic compounds were designed 
and developed for human use. These efforts resulted in the development of Azamulin, which 
entered phase I clinical trials in the 1980s, but no further progress was made due to its low 
solubility in water and short half-life (Hildebrandt et al., 1982). In 2007, Retapamulin, the 
first derivative of pleuromutilin was approved by Food and Drug Administration (FDA) for 
human use as a topical antimicrobial agent to treat skin infections (Wang et al., 2012). 
More recently, several others pleuromutilin derivatives BC-3781, BC-3205 and BC-7013 
have been developed for human use. All of them have already entered phase I clinical studies. 
Most notably amongst these, BC- 3781 (known as, Lefamulin) has successfully completed 
phase II clinical trials (Rubino et al., 2015) and is now in stage III trials as an orally available 
product (Mendes et al., 2016). It has excellent antimicrobial activity against relevant bacteria, 
including MRSA (Ling et al., 2012, Shang et al., 2013). The results demonstrated a 
therapeutic potential of BC-3781 for the treatment of skin infections and bacterial lung 































Figure 7 Chemical structures of pleuromutilin derivatives showing the various synthetic side 
chains at the C14 position. 
 
 
1.2.2 Pleuromutilin biosynthesis pathway and gene cluster 
Pleuromutilin is a diterpene isolated from the basidiomycete fungi C. scyphoides and C. 
passeckerianus. It belongs to the class of secondary metabolites known as terpenes, which are 
produced in fungi through the mevalonate pathway (MEP pathway) (Lange et al., 2000).  
The Basidiomycota have proven to be a valuable group for production of various terpenoid 
compounds. Terpenoids are compounds that originated from the basic of the five carbon units 
dimethylallyl diphosphate (DMAPP) and isopentenyl diphosphate (IPP). In fungi, the 
mevalonate pathway uses acetyl-CoA as substrate and converts it two isoprene units, 
DMAPP and IPP. Sequentially, the two isoprene units are condensed by prenyldiphosphate 
synthase enzymes in a head-to-tail manner to yield a linear hydrocarbon of varying lengths: 
C10 geranyl pyrophosphate (GPP), C15 farnesyl pyrophosphate (FPP), and C20 
Lefamulin 
pleuromutilin tiamulin valnemulin 
azamulin retapamulin BC-7013 
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geranylgeranyl pyrophosphate (GGPP) (Quin et al., 2014, Wawrzyn et al., 2012). Further 
coupling of these hydrocarbons via dephosphorylation and cyclization by terpene synthases/ 
cyclase enzymes can provide the more complex terpenes. Fungal terpene synthases are 
known to have a potential to generate sesquiterpenes (C15), diterpenes (C20) and triterpenes 
(C30) based on the length of the precursor molecules. Moreover, enzymes such as 
cytochrome P450 monooxygenases, oxidoreductases, and various transferases are involved in 
the modification of the terpene scaffold in biosynthetic pathways, to gain the final terpenoid 
compound (Quin et al., 2014). 
Fungi often have many different secondary metabolic pathways and the genes for each are 
typically located in clusters within fungal genomes (Walton, 2000). This feature provides the 
advantage for natural product discovery and bioengineering in that it facilitates genome 
mining approaches in the identification of biosynthetic pathways. Once a gene within a 
secondary metabolic pathway was identified, there is a high possibility that other genes in the 
pathway will be closely associated and therefore relatively easily identified by bioinformatic 
methods (Quin et al., 2013, Wawrzyn et al., 2012). 
The genomic study of pleuromutilin biosynthetic gene cluster in C. passeckerianus was done 
to identify the key genes encoding the production of pleuromutilin in a cluster within the 
same genomic region. According to the study, seven genes have been isolated and sequenced 














The bottleneck enzymes that control the production of pleuromutilin biosynthetic gene cluster 
(Figure 9) are predicted to be Geranyl-geranyl diphosphate synthase (GGS) and Cyclase 
(CYC). GGS is responsible for supplying geranylgeranyl diphosphate (GGPP) to the 
pathway. GGPP is a general precursor of diterpenes. CYC triggers the formation of tricyclic 
structure of pleuromutilin via the cyclisation of GGPP. In addition, there are three 
cytochrome P450s (P450-1, P450-2 and P450-3) involved in the pleuromutilin biosynthetic 
gene cluster. The P450-1 and P450-2 play a critical role to modify the core structure of the 
hydrocarbon skeleton of pleuromutilin by adding hydroxyl groups to C-11 and C-3. The 
short-chain dehydrogenase/reductase enzyme (SDR), the tailoring enzyme within the cluster 
converts the C-3 hydroxyl group to ketone group. Acetyl-transferase (ATF) adds the acetyl 
group to the C-14 OH of mutilin, giving 14-acetyl-mutilin. Finally, P450-3 reduces the acetyl 
side-group of the scaffold resulting in the complete structure of pleuromutilin (Alberti et al., 
2017, Bailey et al., 2016). The pathway has been fully elucidated by heterologous expression 

































Figure 9 Proposed biosynthetic pathway of pleuromutilin.
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1.3 Heterologous expression system 
With the main purpose of my thesis to enhance the production yield of pleuromutilin, 
heterologous expression of the pleuromutilin biosynthesis pathway in different host systems 
will be considered as a rational avenue to improve the pleuromutilin production. Due to the 
very low titres of pleuromutilin produced by the original fungus, Clitopilus passeckerianus, 
an alternative system for pleuromutilin production on a large scale is required. The basic 
principle of heterologous expression involves the identification of genes corresponding in 
biosynthetic pathway and transfer those genes to a different host for synthesis of the 
compound. A critical step for this procedure is the selection of the expression system in 
which pros and cons of several factors have to be considered (Gomes et al., 2016). Thus, 
there are several choices of systems that could be an alternative host for the heterologous 
expression of pleuromutilin as follows. 
 
1.3.1 Heterologous expression in bacteria 
The first and most commonly used host is the bacteria Escherichia coli (E. coli). Due to its 
simplicity, rapid growth under well-defined laboratory conditions on an inexpensive medium, 
high efficiency to accept a foreign DNA and protein expression at a high levels, and most of 
the available cloning and expression vectors are compatible with E. coli, it remains the first 
choice for heterologous expression (Kaur et al., 2018).  
However, in spite of many advantages there are also limitations. E. coli is unable to perform 
post-translational modifications which are often required for functional activity after protein 
synthesis. Protein degradation by proteases enzymes from the host cell can degrade the 
protein of interest. It has an inefficient secretion system to transport and release protein into 
media. The expressed enzyme may produce a potentially toxic product and thus kill the host 
(Kaur et al., 2018, Makrides, 1996). Most importantly for this project, the E. coli system is 
not appropriate for making a broad-spectrum antibiotic that is active against gram negative 






1.3.2 Aspergillus oryzae as secondary host system for heterologous expression 
Aspergillus oryzae (A. oryzae) is a filamentous ascomycete fungus from the family 
Trichocomaceae. It has been widely used as a genetic model for studying a range of 
biological processes. Several studies have shown the potential of A. oryzae, as a prolific 
producer of secondary metabolites (Ehrlich and Mack, 2014, Keller et al., 2005). 
In this study, A. oryzae was chosen as a secondary host system for heterologous expression of 
pleuromutilin gene cluster by taking its two major advantages. Firstly, it is a well 
characterized organism that has a long history in the Japanese food and fermentation industry 
for food production such as sake, miso and soy sauce (Feng et al., 2004). It also has been 
recognized as a Generally Regarded as Safe (GRAS) organism, which means that it does not 
produce any toxins or other dangerous metabolites and therefore is safe to be used for the 
production of enzymes and other molecules intended for human use (Barbesgaard et al., 
1992).   
Secondly, its ability to secrete high level of metabolites (Lubertozzi and Keasling, 2009), as 
well as its well-established culturing methodology and development of genetic manipulation 
tools including several selectable markers, which are essential to rescue transformed colonies, 
have been validated for transforming this fungus. Furthermore, the development of improved 
promoter systems from Aspergillus spp. is expected to ensure a higher yield of heterologous 
expression of foreign genes (Pahirulzaman et al., 2012, Yamada et al., 1997). 
 
 
1.3.3 Using yeast for heterologous expression 
The yeast Saccharomyces cerevisiae is a heterologous expression system that has been 
widely used for the production of many bioactive compounds. This system has several 
attractive characteristics to be used as a tool for the production of foreign metabolites 
including; easy and rapid growth under basic laboratory conditions, inexpensive culturing 
conditions, high biomass and scalable fermentation, an ability for post-translational 
modification and secretion systems, safety and wide use in the food industry, easily 
accessible with the advanced molecular genetic tools (Baghban et al., 2019). However, the 
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disadvantages of this host system are low yields, cell stress due to the presence of the foreign 
genes and lack of a strong inducible promoter (Gellissen et al., 2005).  
Alternative yeast system such as Pichia pastoris, Hansenula polymorpha, Arxula 
adeninivorans have been developed, each system also exhibits different pros and cons 
(Mokdad-Gargouri et al., 2012). For instance, Pichia pastoris offers stronger promoters to 
drive gene expression and higher ability of protein modification, Hansenula polymorpha and 
Arxula adeninivorans can assimilate nitrate and use a wide range of carbon sources 
(Gellissen et al., 2005). The different capability of each system provides an option for a 
heterologous expression host in yeast. From a range of these candidates, the selection for the 
most suitable expression platform will give a desirable targeted product.  
 
1.3.4 Expression of heterologous genes in plant systems 
Over the past decade, the utilization of plant-based expression systems for the production of 
secondary metabolites and recombinant compounds has gained attention. Many studies have 
proven that the system could be an interesting alternative platform to produce important 
recombinant proteins such as antibodies, vaccines and therapeutic pharmaceuticals (Ghag et 
al., 2016). Several applications in plant biotechnology are aimed at the large-scale production 
of natural secondary metabolites. As a molecular platform, plants also offer significant 
advantages over the traditional expression systems like prokaryotic or eukaryotic microbes, 
including lack of animal pathogens, low production costs and easy scalability (Fischer et al., 
2004). Furthermore, dried leaves and seeds containing a recombinant protein can be stored at 
room temperature for long periods of time without loss of its properties (Kolotilin et al., 
2014). 
When considering the secondary metabolites from plants, there are three main categories 
based on their biosynthetic pathways: phenolic compounds, nitrogen-containing compounds 
and terpenes. Focusing on terpenes, the commercial drugs such as artemisinin, taxol, and 
vincristine are all biological products of terpenoids that originated from plants. In common 
with other organisms, terpenoid biosynthesis in plants starts with the universal precursor of 
terpenoids, IPP. However, unlike Saccharomyces cerevisiae and Escherichia coli, plants have 
two pathways responsible for IPP biogenesis; a cytosolic mevalonate (MVA) pathway and a 
plastidic 2-methyl-erythritol 4-phosphate (MEP) pathway (Ikram et al., 2015). The two 
pathways are a well-established strategy to enhance the amount of carbon going into 
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dedicated isoprenoid precursors, pushing metabolic flux through to the final biologically 
active metabolite (Ikram et al., 2015). This makes plants an attractive host system for 
heterologous expression of the pleuromutilin gene cluster. 
The tobacco plant, N. tabacum has a long history as a successful host plant in molecular 
biology and therefore the strongest candidate for the production of secondary metabolite. The 
major advantages of this plant over others include a well-established technology for gene 
transfer and expression, high biomass yields, high seed number and year-round growth and 
harvesting (Makhzoum et al., 2014). Furthermore, tobacco reduces risk of transgenic material 
either in feed crops or the human food chain because it is a non-food or non-feed crop 
(Twyman et al., 2003). 
Heterologous expression of one or a few genes in plants to produce secondary metabolites 
has been successfully presented in several studies. One such example is the alteration of 
steroid compounds using heterologous expression of one animal gene, CYP11A1, a cDNA of 
cytochrome P450scc from the bovine adrenal cortex, in transgenic tobacco. The analysis 
result showed that the expression of this heterologous gene caused an up-regulation and 
formation of steroid compounds such as pregnenolone and progesterone in tobacco plants 
(Spivak et al., 2010). Another example explored the heterologous expression of five 
artemisinin biosynthetic genes from Artemisia annua in Nicotiana tabacum resulting in the 
production of artemisinin precursors, amorphadiene (Zhang et al., 2011), so it may be 














1.4 Summary  
It is without doubt that natural products have been the main source of antibiotic drugs. Their 
discoveries also inspired their derivatives for many novel antibiotics available today. 
However, the discovery and development of antibiotic has been held back due to the length of 
the lead time and high cost of the research, development and clinical trial processes and 
regulatory barriers. This might not have been an issue until the emergence of antibiotic 
resistance and its impact on public health around the world. This phenomenon awakes an 
urgent calling to renew the effort in the discovery and development of new antibiotics, 
especially as there are very few new products in the pipeline. But thanks to advances in 
technology, creation of new molecular methods could open the way forward to discover the 
























1.5 Aims and objectives 
 
The aim of my PhD project is to understand and improve the biosynthesis of pleuromutilin 
and its production. In order to achieve this, I will express the pleuromutilin gene cluster and 
recreate the biosynthetic pathway in three different host systems; Aspergillus oryzae, 
Saccharomyces cerevisiae and Nicotiana tabacum, all of which have already been widely 
used in other studies as hosts for the production of biologically active substances. 
 
There are various objectives that I am aiming to achieve during this project: 
 
 To create improved expression vectors by replacing or improving the promoters 
involved in the expression of the genes responsible for the biosynthesis of 
pleuromutilin in the secondary host A. oryzae, through heterologous expression of the 
gene cluster with the aim of enhancing the production of the antibiotic in this 
secondary host 
 
 To build up the full seven genes of the pleuromutilin biosynthetic pathway in a 
suitable vector for heterologous expression in N. tabacum 
 
 To construct the yeast expression vector containing the genes responsible for the 
biosynthesis of pleuromutilin in S. cerevisiae  
 
 To assess the expression of the genes inserted and evaluate chemical analysis of 
transformed A. oryzae strains, transformed yeast and transgenic plants, then compare 
metabolites production from the three different hosts  
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Chapter 2. Materials and Methods 
 
Materials and Methods 
 
All chemicals and media used within this project were analytical grade or molecular grade, 
and were purchased from Fisher Scientific, Formedium, Melford, Oxoid, Sigma-Aldrich, 
Thermo Scientific, or VWR. 
Deionised water was used to prepare all media and solutions. A standard sterilisation 
procedure by autoclaving at 121oC for 15 minutes was applied to all media, glassware, 
plasticware and solutions before use. 
 
2.1 Microbial strain, growth media and storage condition 
 
All microbial strains used in this project were grown and maintained in a different media and 
growth conditions as shown in Table 1  





Media for growth 
maintenance 
Aspergillus oryzae  NSAR1 
(ΔargB, adeA−, niaD−, sC−) 
MEA+4 at 28oC 
Saccharomyces cerevisiae BY4742 (Y10000) 
(MATα, his3Δ1, leu2Δ0, lys2Δ0, ura3Δ0) 
YPAD at 28oC 
Saccharomyces cerevisiae YPH499 
(MATa ura3-52 lys2-801_amber ade2-
101_ochre trp1-Δ63 his3-Δ200 leu2-Δ1) 
YPAD at 28oC 
Saccharomyces cerevisiae AM109 
(Mat a/α, PGal1-HMG2(K6R):: HOX2, 
ura3, trp1, his3, PTDH3-
HMG2(K6R)X2-::leu2 ERG9/erg9, 
UBC7/ubc7, SSM4/ssm4, PHO86/pho86, 
derived from AM102) 
YPAD at 28oC 
Bacillus subtilis  ATCC 6633 TSB at 28oC 
Escherichia coli One shot® ccdB SurvivalTM 2 T1R LB at 37oC 
Agrobacterium tumefaciens LBA4404 
 
LB at 28oC 
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Table 2 Microbial media components. 
 
Media Components 
MEA+4 15 g/L malt extract, 1.5 g/L methionine, 2 g/L ammonium sulphate, 0.1 g/L 
adenine, 1 g/L arginine / 15 g/L agar 
YPAD 10 g/L yeast extract, 20 g/L bactopeptone, 20 g/L D-glucose, 40 mg/L adenine 
hemisulfate / 15 g/L agar 
LB 10 g/L NaCl, 10 g/L tryptone, 5 g/L yeast extract / 15 g/L agar 
TSB 30 g/L tryptic soy broth / 15 g/L agar 
 
Table 3 List of antibiotics used in this project. A stock solution was prepared, then calculated 









Ampicillin Water 100 mg/mL 100 µg/mL 
Kanamycin Water 50 mg/mL 50 µg/mL 
Spectinomycin Water 50 mg/mL 250 µg/mL 
Rifampicin Methanol 20 mg/mL 20 µg/mL 
 
For short-term storage, all fungal, yeast and bacterial cultures were stored on agar plates with 
appropriate medium and supplement at 4oC. 
For long-term storage, a plug of growing mycelia of fungal strain, including transformant 
strains were stored by adding sterilised glycerol (40% v/v in water) and quickly frozen in 
liquid nitrogen before storage at -80oC. Yeast and bacterial liquid cultures were added to an 
equal volume of sterilised glycerol (40% v/v in water) and rapidly frozen in liquid nitrogen 






2.2 Molecular methods 
2.2.1 Plasmid DNA purification  
 
Plasmid DNA from E. coli was purified by using the GeneJET Plasmid Miniprep Kit 
(Thermo Scientific) according to the manufacturer’s instructions. In brief, the overnight 
culture was pelleted and treated with an alkaline lysis to release the plasmid DNA. The 
cleared lysate was then neutralised to precipitate the cellular debris while maintaining the 
plasmid DNA. The supernatant containing the plasmid DNA was loaded into a spin column 
and the plasmid DNA was absorbed onto a silica membrane. After several washing, the 
impurities were washed away, and the purified plasmid DNA was then eluted with a small 
volume of elution buffer. 
Plasmid DNA from yeast was purified by using the Zymoprep TM Yeast Plasmid Miniprep I 
(Zymo Research) according the manufacturer’s instruction. Firstly, yeast cells from an 
overnight culture were collected and resuspended in digestion buffer. Zymolase enzyme was 
added to disrupt the yeast cell wall and produce protoplast. The mixture was incubated for 1 
hour at 37oC. The lysate mixture was then treated with lysis and neutralising buffer to 
precipitate the cell debris. The supernatant containing the plasmid DNA was then rescued by 
isopropanol precipitation. Finally, the pelleted plasmid DNA was resuspended with small 
volume of TE buffer. 
 
2.2.2 Small-scale fungal genomic DNA purification 
 
Small scale fungal DNA purification was employed as described by (Liu et al., 2000). The 
protocol started by picking up a 1 mm3 clump of mycelia from the agar plate and putting into 
1.5 mL Eppendorf tube containing 500 µL of lysis buffer (400 mM Tris-HCl [pH 8.0]), 60 
mM EDTA [pH 8.0], 150 mM NaCl, 1% sodium dodecyl sulphate). The mycelia were then 
disrupted with a sterile loop and left at room temperature for 10 min. After that 150 µL of 
potassium acetate solution (60 mL of 5 M potassium acetate, 11.5 mL of glacial acetic acid 
and 28.5 mL of distilled water, pH 4.8) was added, then briefly vortexed, and centrifuged at 
10,000 x g for 1 min. The supernatant was transferred to a new tube and centrifuged at 10,000 
x g for 1 min once again to remove all precipitate. After transferring the supernatant to a new 
tube, an equal volume of isopropanol was added and briefly mixed by inversion, then 
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centrifugation at 10,000 x g for 2 min. The supernatant was discarded and 300 µL of 70% 
ethanol was used to wash the pellets, centrifuged at 10,000 x g for 1 min and the supernatant 
was discarded. The DNA pellet was air dried and dissolved in 50 µL of TE buffer (10 mM 
Tris-HCl. 1 mM EDTA, pH 8.0) before storing at -20oC.  
 
2.2.3 Restriction digestion of DNA 
 
Restriction digestion was done on the plasmid vector to obtain a linear backbone prior 
proceeding with yeast-based homologous recombination. It was also carried out for screening 
and confirming the identity of the correct construction of the plasmid after E. coli plasmid 
DNA purification. All restriction enzymes were purchased from Thermo Fisher Scientific and 
restriction digestion reaction was performed by following the manufacture’s protocols. 
The restriction digestion mixture was set up with 1 µg of plasmid DNA, 1 µL of 10X 
FastDigest Green Buffer, 1 µL FastDigest enzyme and made up to the final volume of 10 µL 
with sterile water. The mixture was incubated for 30 minutes – 1 hour at 37oC. Unless 
specified, the components of restriction digestion mixture were combined as indicated. 
 
2.2.4 PCR 
2.2.4.1 Conventional PCR 
 
In order to amplify cDNA fragments, check ligation reactions, confirm transformant strains 
and for colony screening, conventional PCR reactions were carried out using DreamTaq 
Green DNA Polymerase (Thermo Scientific). A 2X DreamTaq Green Mix was prepared as 
follows: 2 mL of 10X DreamTaq Green Buffer, 400 µL of 10 mM dNTPs, 100 µL of DNA 
Polymerase (5U/ μl), then made up to 10 mL with sterile deionised water. The aliquot of 500 
µL 2X DreamTaq Green Mix was prepared in 1.5 mL Eppendorf tube and stored at -20oC. 
When needed the PCR reactions were set up with the following components; 10 μL of 2X 
DreamTaq Green Mix, 1 µL of 10 μM forward primer, 1 μL of 10 μM reverse primer, 1 μL 
(1-10 ng) of template DNA and the 20 μL final volume was made up by sterile water. 
Cycling parameters for conventional PCR were initial denaturation at 95°C for 3 minutes, 
then 35 cycles of denaturation at 95°C for 30 seconds, annealing at “Tannealing” for 30 seconds 
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and extension at 72°C for 1min/1kb (depending on the length of the expected PCR product), 
then followed by a 10 min final extension at 72°C. The PCR reactions were carried out by 
using a PTC-200 DNA Engine Thermal Cycler (Biorad). 
 
2.2.4.2 Colony PCR 
Colony PCR was performed in order to detect the presence of insert DNA in plasmid 
constructs from E. coli transformant colonies growing on selective plates after 
transformations with plasmids, using 2X DreamTaq Green Mix. Instead of the template 
DNA, half a colony was picked up from the plate and placed into a PCR tube. The same 
cycles as for common PCR were followed, however the initial denaturation step at 95°C was 
extended to 10 minutes. The other half colony was used for further analysis when the PCR 
reaction had amplified a band of the expected size. 
 
2.2.4.3 High-fidelity PCR 
When PCR products needed to be cloned into expression vectors, Phusion High-fidelity DNA 
Polymerase (Thermo Scientific) was used to amplify the fragment, the reaction mixture was 
prepared as follows: 0.2 µL Phusion High-fidelity DNA Polymerase (2U/µL), 4 µL 5X 
Phusion HF buffer. 0.4 µL 10 mM dNTPs, 1 µL 10 μM forward primer, 1 µL 10 μM reverse 
primer, 1 µL template DNA (1-10 ng) and then sterile water was used to made up the final 
volume to 20 µL. 
Cycling parameters for high-fidelity PCR were; initial denaturation at 98°C for 30 seconds, 
then 35 cycles of denaturation at 98°C for 10 seconds, annealing at “Tannealing” for 30 seconds 
and extension at 72°C for 20 sec/1kb (depending on the length of the expected PCR product), 
then followed by a 10 min final extension at 72°C. The PCR reactions were carried out by 










All primers used in this study were purchased from IDT (Integrated DNA Technologies). 
Each primer was diluted with sterile water at 1:10 ratio to give a concentration of 10 µM and 
stored at -20oC. 

















Amplification of ArgB to be 




ArgB RR * CTGTAATAC GACTCACTAT AGGGAATATT A 
CATACCCGTCAACTCATCAG 
64.2 




Amplification of ptrA to be 




ptrA RR (1) TCCTCGCCCTTGCTCACCAT 
GTTTCAAGTTGCAATGACTATCATCTGTTA 
67.9 




Amplification of GFP to be 















Amplification of pgkA to be 













Amplification of GFP to be 














Amplification of pdcA to be 




pdcA RR (1) TCCTCGCCCTTGCTCACCAT TGTA 





















Amplification of GFP to be 
























Amplification of pdcA to be 



























71.0 Amplification of pdcA to be 

























pdcA-SDR FF* ATGACCCACTGGGGTTTTAGGAGGTCAATT 
TGACTGTCACGCCAGCGACT 
71.0 Amplification of pdcA to be 
















pdcA-SDR RR* GCCTGTGACGATTGCGACCTTGCCTTCCAT 
TGTAAGGACTCAGTAAGAGG 
69.4 
GGS FF F1 * TAGAGCGGATGTGGGGGGAGGGCGTGAAGA
C AA A ATGAGAATACCTAACGTCTT TCTCT 
70.4 Amplification of GGS 
fragment 1 and introduce 
internal mutagenesis sites to 





GGS RR F1 ** ATCAATTAGTAGGGATGCATTATGAAGGTCCT
CAATGGCCTTTGT TACGC 
66.4 
GGS FF F2 ** GGCCATTGAGGACCTTCATAATGCATCCCTAC
TAA TTGATGACATCGAAGATGAGTCTGC 
68.1 Amplification of GGS 
fragment 2 and introduce 
internal mutagenesis sites to 




GGS RR F2 ** GCAACCTGTGTGCCACCTGTTTTCATGCCAA
GGTCATAGA CGTCTTGAAG 
69.3 




Amplification of GGS 
fragment 3 and introduce 
internal mutagenesis sites to 





















Cyclase FF F1 * TAGAGCGGATGTGGGGGGAGGGCGTGAAGA
CAAAATGGGTCTATCTGAAGATCTTCATG 
70.5 Amplification of Cyclase 
fragment 1 and introduce 
internal mutagenesis sites to 













69.3 Amplification of Cyclase 
fragment 2 and introduce 
internal mutagenesis sites to 
be use in yeast homologous 
recombinant 
804 









68.8 Amplification of Cyclase 
fragment 3 and introduce 
internal mutagenesis sites to 









Cyclase FF F4 CAGGCGCTTGTCCGTCTCCTTTTCGAGCACG
GAAAGGGCAACCTTAAATC 
70.7 Amplification of Cyclase 
fragment 4 and introduce 
internal mutagenesis sites to 









Cyclase FF F5 GTCATCAGATCAATGAAGAACGAGGCTCTCG
CGATTTGGTGGACGTTTTC 
68.0 Amplification of Cyclase 
fragment 5 and introduce 
internal mutagenesis sites to 




Cyclase RR F5 * ACGACTCACTATAGGGAATATTAAGGAAGAC
AATCAATGGTGGATTCCATTGCTCCCG 
67.6 




Amplification of P450-1 
fragment 1 and introduce 
internal mutagenesis sites to 





P450-1 RR F1 TATTACCCTG CTTGTCAAGA ATAGTCCGAA 
CAGCCTTTGG ACTGTTCAGA 
67.4 
P450-1 FF F2 TTCGGACTAT TCTTGACAAG CAGGGTAATA 
TCACAGGAGA TCGGCCATTT TCGCC 
69.0 
Amplification of P450-1 
fragment 2 and introduce 
internal mutagenesis sites to 




P450-1 RR F2 CTTGGCGTTA GGTAATTGTG GATACCTTTG 















P450-1 FF F3 CAAAGGTATC CACAATTACC TAACGCCAAG 
TGCCTTGAGT GGCTACATAC 
67.2 
Amplification of P450-1 
fragment 3 and introduce 
internal mutagenesis sites to 




P450-1 RR F3 TCCACAATGG TTTTCCAGCC GGCCCCGGGG 
AAACCGCGAG GGATGTAGTC 
74.5 
P450-1 FF F4 CCCCGGGGCC GGCTGGAAAA CCATTGTGGA 
TGAATTCAAG GATTTCCGTA 
71.7 
Amplification of P450-1 
fragment 4 and introduce 
internal mutagenesis sites to 




P450-1 RR F4 AGAATACACG ATTCGATGTA CGATATCGTG 
GTTTTCGCGC CGGCGTCCAA 
70.0 
P450-1 FF F5 CACGATATCG TACATCGAAT CGTGTATTCT 
TGCTCTTATC GCCCACCCGA 
67.0 
Amplification of P450-1 
fragment 5 and introduce 
internal mutagenesis sites to 




P450-1 RR F5 ACAGG AAATCGGGAT TGACATCTTC 
AGATAAGCCT GGCTTCGTGC CGTTT 
69.6 
P450-1 FF F6 AGGCTTATCT GAAGATGTCA ATCCCGATTT 
CCTGTTCGGT GCTGGACGTA 
68.8 
Amplification of P450-1 
fragment 6 and introduce 
internal mutagenesis sites to 




P450-1 RR F6 GTAAAAATTG AATGCCCAAC AGAGCCTCAT 
GATGAATAGA CCAGTTGATC GTTTT 
66.3 
P450-1 FF F7  ATGAGGCTCT GTTGGGCATT CAATTTTTAC 
CCAGATTCTT CAAACAAGGA 
66.8 
Amplification of P450-1 
fragment 7 and introduce 
internal mutagenesis sites to 




192 P450-1 RR F7 CT ACAACGCAGC GAACGCTTCC 
TTAATCAGAT CTTCCTTCAT CTTATCTCGA 
GGT 
67.7 
P450-1 FF F8 ATGAGGCTCT GTTGGGCATT CAATTTTTAC 
CCAGATTCTT CAAACAAGGA 
66.8 
Amplification of P450-1 
fragment 8 and introduce 
internal mutagenesis sites to 




225 P450-1 RR F8 AC GACTCACTAT AGGGAATATT AAG 
GAAGAC AA CT ACAACGCAGC 
GAACGCTTCC TTA 
67.9 
P450-3 FF F1 TAGA GCGGATGTGG GGGGAGGGCG T 
GAAGAC AA A ATGGCTCCGT CAACGGAACG 
TGCTC 
GAGATGGTTT GATGAGGTAC GCCCATAGGA 
GTCACAGGCC TCCAGCGGTA 
74.0 
Amplification of P450-3 
fragment 1 and introduce 
internal mutagenesis sites to 























P450-3 FF F2 TCCTATGGGC GTACCTCATC AAACCATCTC 
AGATGACGTT TACAGGGAAT 
68.0 
Amplification of P450-3 
fragment 2 and introduce 
internal mutagenesis sites to 




P450-3 RR F2 TTCGGTCAAG TATCGCTCAG GCCGGAATTC 
GTCTGGCTGG GGGTAATCGG TTTCGTCGTT 
72.9 
P450-3 FF F3 CTGAGCGATA CTTGACCGAA GATGGTAAGC 
CTAACAAGGC TGTCAGAGAT CCCTTTGATA 
68.8 
Amplification of P450-3 
fragment 3 and introduce 
internal mutagenesis sites to 




P450-3 RR F3 AC GACTCACTAT AGGGAATATT AAG 
GAAGAC AA CTAGCCACT AGCAGGCTTC 
GTGAAC 
67.6 
ATF FF F1 TAGA GCGGATGTGG GGGGAGGGCG T 
GAAGAC AA A ATGAAGCCCT TCTCACCAGA 
ACTTC 
72.1 
Amplification of ATF 





ATF RR F1 AC GACTCACTAT AGGGAATATT AAG 
GAAGAC AA CTAC TGTGCTACAC 
GAGGGGGATT C 
67.5 
SDR FF F1 TAGA GCGGATGTGG GGGGAGGGCG T 
GAAGAC AA A ATGGAAGGCA AGGTCGCAAT 
CGTCA 
73.6 
Amplification of SDR 
fragment 1 and introduce 
internal mutagenesis sites to 




SDR RR F1 TGACTCTGTC CCATACATCG TCCTCGAAGG 
TCAACGCGGT CTGGAAGTAG 
70.0 
SDR FF F2 CCTTCGAGGA CGATGTATGG GACAGAGTCA 
TCGATGTCAA CCTGGCTGCA 
70.5 
Amplification of SDR 
fragment 2 and introduce 
internal mutagenesis sites to 




SDR RR F2 AC GACTCACTAT AGGGAATATT AAG 
GAAGAC AA CT AAATGACACT 
CCACCCGTTA TCG 
66.4 
L0 GGS FF *** GG GAAGAC GC CTCA AATG ATGAGAATAC 
CTAACGTCTT TCTCTCTTAC CTGCGACAAG 
TC 
68.7  
Amplification of L0-GGS 
fragment introduced BpiI 





L0 GGS RR *** GG GAAGAC GC CTCG AAGC CTA 


















L0 Cyclase FF 
*** 
GG GAAGAC GC CTCA AATG ATGGGTCTAT 
CTGAAGATCT TCATGCACGC GCCCGAACCC 
TC 
71.9  
Amplification of L0-Cyclase 
fragment introduced BpiI 






L0 Cyclase RR 
*** 
GG GAAGAC GC CTCG AAGC TC 









Amplification of L0-KanR 
fragment introduced BpiI 












L0 P450-1 FF 
*** 
GG GAAGAC GC CTCA AATG ATGCTGTCCG 
TCGACCTCCC GTCTGTTGCG AACTTGGATC 
CC 
73.1 
Amplification of L0-P450-1 
fragment introduced BpiI 





L0 P450-1 RR 
*** 
GG GAAGAC GC CTCG AAGC CT 




L0 P450-2 FF 
*** 
 





Amplification of L0-P450-2 
fragment introduced BpiI 






L0 P450-2 RR 
*** 
 





L0 P450-3 FF 
*** 




Amplification of L0-P450-3 
fragment introduced BpiI 





L0 P450-3 RR 
*** 



















L0 ATF FF *** GG GAAGAC GC CTCA AATG ATGAAGCCCT 
TCTCACCAGA ACTTCTGGTT CTATCTTTCA 
TT 
68.9 
Amplification of L0-ATF 
fragment introduced BpiI 





L0 ATF RR *** GG GAAGAC GC CTCG AAGC CTAC 
TGTGCTACAC GAGGGGGATT CCATTCCCCC 
CGGTACAG 
73.8 
L0 SDR FF *** GG GAAGAC GC CTCA AATG ATGGAAGGCA 
AGGTCGCAAT CGTCACAGGC GCATCCAATG 
GC 
73.3 
Amplification of L0-SDR 
fragment introduced BpiI 





L0 SDR RR *** 
 
GG GAAGAC GC CTCG AAGC CT 








Amplification of GGS to be 














Amplification of Cyclase to 










* Primers used to amplify target genes for yeast homologous recombination. The sequences 
highlighted in red are the flanking sequences which are homologous to the sequence of the plasmid 
backbone. 
** Internal primers used to amplify target genes for yeast homologous recombination. BpiI or BsaI 
recognition sites were found in the genes and needed to be removed, so the internal primers were 
designed to contain a single mismatch nucleotide highlighted in red in order to make a silent mutation 
but not change the encoded amino acids. 
*** Primers used to amplify target genes for Golden Gate assembly level 0. The sequences 
highlighted in red are BpiI recognition sequences that were introduced in the sequence to generate the 
4 nucleotide overhangs after digestion. The sequences highlighted in blue are the compatible 
sequence overhangs that will be combined with the L0 destination vector after ligation.  
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2.2.6 Gel electrophoresis 
 
To visualise RNA, genomic or plasmid DNA after nucleic acid isolations, as well as for PCR 
amplification products and restriction digestion fragments, gel electrophoresis was performed 
on 1% w/v agarose gel. The gel was prepared by dissolving a desired amount of agarose 
(Type I, Molecular Biology Grade, Bioline) in 1X TAE buffer (40 mM Tris, 20 mM acetic 
acid, 1 mM EDTA) mix with Midori Greene Advance Nucleic Acid Stain. The agarose/buffer 
mixture was melted by heating in a microwave until the agarose has completely dissolved. 
The agarose was cooled prior to pouring into a gel caster. Gels were run for 30 min at 100 V 
for separation in horizontal chamber containing 1X TAE buffer. Five μl of Hyperladder I 
(Bioline) or 2-log ladder (New England Biolabs) was run each time in the first lane of the 
agarose gel to estimate the size (bp) and concentration (ng/band) of the nucleic acids. The 
gels were then analyzed under UV light exposure using the Universal hood II gel Imager 




















2.2.7 Gel Purification 
 
In order to isolate the desired fragment of intact DNA (PCR product) from agarose gel after 
electrophoresis, bands were excised from the gel and purification was carried out using 
GeneJET PCR Purification Kit (Thermo Scientific) according to manufacturer’s instructions 
with products eluted in 20 µL water. 
 
2.2.8 Cloning of PCR product 
 
In order to store the PCR products for further use, cloning was performed by using CloneJET 
PCR Cloning Kit (Thermo Scientific). The purified PCR product was cloned into the blunt 
cloning vector pJET1.2 by following the manufacturer’s instructions and recovered in E. coli 











Figure 11 Map of pJET1.2/blunt. 
 
 
2.2.9 Sequencing  
 
In order to determine the nucleic acid sequences of the constructed plasmids, the plasmid 
samples were sent to GATC Biotech for sequencing. According to the company’s instruction, 
the sample mixture was prepared by adding 100 ng/µL of plasmid DNA with 5 µL of primer 
(5 µM). The Clone Manager Suite 7 software was used to analyse the output data. 
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2.2.10 Protoplast-mediated transformation of A. oryzae  
The protoplast-mediated transformation technique was carried out in order to transfer 
plasmids into A. oryzae. The A. oryzae strain NSAR1 (nitrate non-utilisation, sulphate non-
utilisation, arginine auxotrophy and adenine auxotrophy) was used as a recipient (Jin et al., 
2004). Protoplast preparation and subsequent transformation was carried out following the 
procedure described by (Halo et al., 2008), which employs polyethylene glycol (PEG) and 
calcium chloride; the appropriate auxotrophy of A. oryzae strain was used as a selectable 
marker for the transformations on CZD plates (35 g/L Czapek-dox broth, 1 M sorbitol, 1.5 
g/L methionine, 0.1 g/L adenine, 2 g/L arginine, 2 g/L ammonium sulphate, 15 g/L agar; the 
nutrient supplement will be left out according to auxotrophy selection of each strain). 
The spores of A. oryzae NSAR1 or A. oryzae transformant strains were collected from a 10-
day-old plate, filtered through Miracloth and used to inoculate into 50 mL GN liquid medium 
(10 g/L D-glucose, 20 g/L Nutrient broth no.2 (Lab M), incubated overnight at 28oC, 200 
rpm. The culture was harvested by centrifugation at 8000 x g for 10 minutes. After discarding 
the supernatant, the pellets were resuspended in 10 mL protoplasting solution (20 g/L lysing 
enzyme from Trichoderma harzianum, 10 g/L Driselase from Basidiomycetes sp., 0.8 M 
NaCl), and incubated on a gently mixing roller at room temperature for 1.5 hours. The 
protoplasts were separated from hyphae by filtering through Miracloth. The protoplast filtrate 
was then centrifuged at 3000 x g for 5 minutes and resuspended in 100 µL of solution 1 (0.8 
M NaCl, 10 mM CaCl2, 50 mM Tris-HCl [pH 7.5]). The concentration of protoplast 
suspension was measured by using a haemocytometer and diluting the suspension to 1x107 
m/L with solution 1. A 100 µL aliquot of protoplast suspension was used for each 
transformation reaction. Then each transformation mixture was added with 5-10 µg of 
plasmid DNA and incubated on ice for 2 minutes. Afterwards, 1 mL of solution 2 (600 g/L 
PEG 3350, 10 mM CaCl2, 50 mM Tris-HCl [pH 7.5]) was added to the mixture and incubated 
at room temperature for another 20 minutes. 
Lastly, the appropriate melted selective CZD top medium was added and mixed with the 
transformation mixture prior overlay over selective CZD base medium lacking a supplement 
for auxotrophic selection marker. The plates were incubated at 28oC for 3-5 days until the 
transformant colonies formed. The subculturing process of transformant colonies were 
performed for at least three times to ensure the stability of genes inserted of the transformant 
strains.   
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2.2.11 Transformation of E. coli 
2.2.11.1 Preparation of electrocompetent E. coli 
 
Electrocompetent cells of E. coli strain ccdBS were prepared prior to transformation 
according to the procedure published by (Nishimura et al., 1990). A colony from fresh 
streaked E. coli was inoculated into 5 mL of LB media and incubated overnight at 37°C on a 
rotary shaker at 225 rpm. On the next day, four 250 mL flasks each containing 100 mL of LB 
medium were inoculated with 1 mL overnight culture E. coli per flask, then incubated as 
before until OD600 = 0.3 was reached. After that, cell cultures were decanted into 8 of 50 mL 
Falcon tubes and centrifuged at 2500 x g for 10 min at 4°C. All manipulations were carried 
out with the cell on ice. After discarding the supernatants, each cell pellet was resuspended in 
50 mL ice cold sterile water and centrifuged as before. After discarding the supernatants, 
each cell pellet was resuspended in 25 mL ice cold sterile water and the samples were pooled 
into 4 tubes, then centrifuged as before. After discarding the supernatants, each cell pellet 
was resuspended in 10 mL ice cold 20% glycerol (filter sterilized) and the samples were 
pooled into a single tube. After that, 10 mL ice cold 20% glycerol was added, and the tube 
was then centrifuged at 2000 x g for 10 min at 4°C. Finally, the cell pellet was resuspended in 
1.2 mL ice cold 20% glycerol and divided into 50 μL aliquots, which were rapidly transferred 
into sterile Eppendorf tubes and frozen in liquid nitrogen. The cells were stored at - 80°C. 
 
2.2.11.2 Transformation of electrocompetent E. coli with plasmid DNA by 
electroporation 
 
Electrocompetent E. coli ccdBS cells were thawed on ice. Fifty μL of cells were mixed gently 
with 10 μL plasmid solution. The cell mixture was then added into the electroporation 
cuvette, wiping off excess moisture outside the cuvette and placed into the Biorad 
electroporator. The electroporator was set at 2500 V using the default EC2 program. After 
pulsing the cuvette was removed and 200 μL of SOC (0.5% [w/v] yeast extract, 2% [w/v] 
tryptone, 10 mM NaCl, 2.5 mM KCl, 20 mM MgSO4, 20 mM glucose filter sterilised) was 
added. Afterward, the SOC-cell mixture was transferred to an Eppendorf tube and incubated 
at 37°C for 1 hour. Finally, 200 μL of the transformation mixture were plated onto selective 
LB medium supplemented with 50 μg/mL ampicillin and incubated overnight at 37°C. 
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2.2.12 Yeast Homologous Recombination for plasmid construction 
 
Yeast recombination is a technique used to recombine DNA fragments into plasmids using 
the yeast S. cerevisiae. The DNA fragments to be inserted into the backbone plasmid were 
amplified through PCR by using Phusion High-fidelity DNA polymerase. Primers used 
contained 30 bp of sequence homology to the plasmid. Backbone plasmid were extracted 
from E. coli and digested with the appropriate restriction enzyme. Yeast transformation was 
described by (Gietz and Woods, 2002). A single colony of yeast S. cerevisiae Y10000, 
YPH499 or AM109 was grown overnight in 10 mL YPAD liquid medium at 28oC and shaken 
at 200 rpm. The starter culture was then used to inoculate a flask containing 40 mL of YPAD 
and was shaken further for another 5 hours. After that the culture was centrifuged at 8000 x g 
for 5 minutes. At room temperature, the pellets were washed several times with 25 mL sterile 
water and centrifuged as before. The water was discarded, and pellets were resuspended with 
1 mL of 0.1 M LiOAc solution and transferred to 1.5 mL Eppendorf tube. Cells were pelleted 
again and resuspended in 400 µL of 0.1 M LiOAc solution. An aliquot of 50 µL of pellets 
suspension for each transformation was divided into new 1.5 mL tubes and then centrifuged.   
 
Each transformation tube contains; 240 µL of 50% PEG 3350 solution, 36 µL of 1 M LiOAc 
solution, 50 µL of salmon sperm single-stranded DNA (2 mg m/L) and 34 µL of DNA 
fragments (typically 10 µL of linearised backbone plasmid and 5 µL of each PCR product the 
sterile distilled water was used to made up final volume). The mixture was mixed well and 
incubated at 30oC for 30 minutes, then at 42oC for another 30 minutes. The cell mixture was 
then centrifuged and resuspended in 500 µL of sterile water. The yeast transformation 
mixture was plated on synthetic medium SM lacking an appropriate auxotrophic marker (1.7 
g/L Yeast nitrogen base without amino acid, 5 g/L ammonium sulphate, 20 g/L D-glucose, 
0.77 g/L Yeast Synthetic Drop-out medium supplements, 20 g/L agar) and incubated at 28oC 
for 2-3 days. The transformant yeast colonies were collected and yeast plasmid DNA 
purification was carried out using the Zymoprep Yeast Plasmid Miniprep I as described 
previously. Purified yeast plasmid was rescued into E. coli competent cells in order to have a 
higher number of copies. After E. coli transformation, colony PCR was carried out to check 
for the presence of the desired DNA from the obtained transformation colonies. The positive 
colonies were then purified, and restriction digestion reaction was performed to confirm the 
correct construction.   
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2.2.13 Plate-based assay for assessing antibacterial activity 
 
The plate-based assay against Bacillus subtilis was used to study an antibacterial activity of 
the fungal transformant strains following the procedure as defined by (Hartley et al., 2009). 
In brief, spores of B. subtilis were prepared by inoculating 50 mL TSB broth and grown 
overnight at 28°C. The horizontal pre-prepared TSA agar base medium in a Thompson bottle 
was inoculated over the surface with one mL of the overnight culture and incubated at 30°C 
for 6 days. The spores of B. subtilis were harvested using 100 mL of sterile distilled water. 
The spores were then activated by heat at 70°C for 30 minutes and stored at 4°C until needed. 
To assess an antibacterial activity of the fungal transformants strains, A plug of each 
transformant strain was used to inoculate onto the central of CMP agar plates (35 g/L 
Czapek-dox broth premix, 20 g/L maltose, 10 g/L peptone, 15 g/L agar) and grown at 28°C 
for 3 days. Five mL of melted TSAg (30 g/L tryptic soy broth premix, 5 g/L agar, 10 g/L 
glucose) overlay medium containing 5 µL of B. subtilis spores and 37.5 µL of 4 % TTC 
(2,3,5-Triphenyl-2H-tetrazolium chloride) was poured onto each plate and allowed it to 
solidify to form uniform layer. The plates were then incubated overnight at 28°C, and the 
clearing zone were observed and measured. 
 
2.2.14 Golden Gate Assembly protocol 
 
Golden Gate reactions were set up for generating the final expression vector containing genes 
involved in the Pleuromutilin biosynthetic pathway as described by (Weber et al., 2011). 
Restriction-ligation reactions were set up in one tube reactions containing: ~100 ng of 
acceptor plasmid, ~200 ng of inserted PCR product/ or each DNA component of plasmid 
containing each module (2:1 molar ratio was the appropriate ratio for insert and acceptor 
vector), 1 µL of required restriction enzyme (BsaI or BpiI), 1 µL of T4 DNA ligase enzyme, 
2 µL T4 DNA ligase buffer, 2 µL 10X FastDigest Green Buffer and made up to final volume 
of 20 µL with sterile water.  
The reaction was performed in a thermocycler using the following program: initial incubation 
at 37oC for 30 seconds, then incubated at 37oC for 3 minutes and 16oC for 5 minutes, both 
steps repeated 50 times, followed by incubation at 50oC for 5 minutes and 80oC for 5 
minutes. The reaction mixture was transformed into competent E. coli cells and the 
transformation was plated on LB plates containing the appropriate antibiotic. For blue/white 
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selection, plates were supplemented with X-gal (2% w/v dissolved in DMSO) prior to 
plating. 
 
2.2.15 Agrobacterium infiltration of N. tabacum 
 
The Agrobacterium infiltration was performed as described in Voinnet et al., (2003). 
Agrobacterium tumefaciens LBA4404 wild type strain and transformant strains containing 
the pL2 expression vector were streaked on LB agar plates containing appropriate antibiotic 
and grown at 28°C for 48 hours. A single colony was picked and inoculated into 5 mL of LB 
media supplemented with appropriate antibiotic and incubated further at 28°C for 48 hours 
with 300 rpm. After that 25 mL of LB media plus 10 mM MES pH 5.7 (adjusted with KOH), 
150 µM acetosyringone and the selective antibiotics was inoculated with 1 mL overnight 
culture and grown overnight at 28°C. Subsequently, the bacterial pellets were precipitated 
and washed once with the equal volume of MES buffer pH 5.7 and then resuspended in 
MMA buffer (10 mM MgCl2, 10 mM MES pH 5.7, 150 µM acetosyringone). The OD600 was 
adjusted to 0.5-1.5 and the bacterial cells were stored at room temperature for 2-5 hours prior 
used for infiltration.  
In order to perform an Agrobacterium syringe infiltration, the 4-6 -week-old N. tabacum 
plants were selected for transformation. Leaves were gently infiltrated with A. tumefaciens 
using a syringe to force the solution through the stomata of the lower leaf surface. A 
successful infiltrate was observed as a spreading wetting area in the leaves. The infiltrated 
plats were then maintained in a growth chamber at 25oC with a 16 h/ 8 h of light/dark 
photoperiod condition for 3 days. Afterwards, the infiltrated region on leaves were harvested 











2.3 Chemical analysis 
2.3.1 Fungal chemical extractions  
 
Chemical extraction of fungal culture was performed in order to assess the production of 
metabolites by fungal strains. A 100 mL of CMP broth in a 250 mL flask was inoculated with 
1 mL of 2.5x107 m/L spore solutions from NSAR1 and from A. oryzae transformant strains, 
and grown on shaking incubator at 28oC, 200 rpm for ten days. Growing mycelia cultures of 
A. oryzae NSAR1 and A. oryzae transformants were each harvested and homogenised after 
adding an equal volume of water. Then concentrated HCl was used to adjust the pH to a value 
of 3 units. Following that an equal volume of ethyl acetate was added to the culture, and the 
mixture was stirred for 20-30 minutes at room temperature. The organic phase and water 
phase were separated in a separating funnel. While the organic phase was collected, the water 
phase was then extracted again with an equal volume of ethyl acetate for three times and 
these organic extracts were pooled. 
The organic extract was dried using anhydrous MgSO4 and concentrated by evaporating 
using a rotary evaporator at 30oC, to remove the solvent. The dried crude extract was 
resuspended in methanol (10 mg m/L), and an equal volume of hexane was added, followed 
by shaking in a separation funnel to allow the defatting of the sample. The methanol phase 
was subjected to two additional rounds of defatting, while the hexane phase was removed. A 
pre-weighted vial was used to collect the methanol phase and dried under a flow of dry N2 
gas and weighted again. Dried crude extract was resuspended in acetonitrile to a 
concentration of 10 mg m/L and transferred to a LC-MS vial.  
 
2.3.2 Yeast chemical extractions 
 
Chemical extractions with hexane were undertaken on yeast liquid cultures in order to 
analyse the metabolite produces by the yeast transformant strains. The extraction procedure 
was applied as described by (Zhuang and Chappell, 2015). The yeast culture was added with 
the equal volume of acetone and mixed vigorously for 5 minutes to lyse the cells. The cell 
mixture was then incubated at room temperature for 10 minutes. Following that, equal 
volume of hexane was added and mixed well again, the mixture was then centrifuged for 5 
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minutes at maximum speed. The organic layer was collected and concentrated under a N2 
stream before being analysed through TLC. 
 
2.3.3 Thin layer chromatography (TLC) 
Thin layer chromatography (TLC) was performed to optimised an appropriate solvent system, 
used to separate the components of a compound from crude extract mixture. It was also used 
as an alternative method to screen transformant prior to LC-MS and for GC transformants 
where LC-MS failed to detect the product. The crude extract was spotted onto a 2x10 cm 
aluminium-backing TLC plate (TLC silica gel 60 F254; Merck, Darmstadt, Germany), and 
developed in an appropriate ratio of petroleum ether and ethyl acetate. To visualise the 
compounds and recorded the Rf, the plate was immersed in potassium permanganate solution 
(1.5 g of KMnO4, 10 g of K2CO3 and 1.25 mL of 10% NaOH in 200 mL of water).  
 
2.3.4 Liquid chromatography-mass spectrometry (LC-MS) analysis 
The LC-MS was performed to screen the crude extracts from fungal transformants for the 
production of metabolite compounds. The analysis was performed on a Waters 2767 HPLC 
system with a Waters 2545 pump system. Chromatographic separation was achieved using a 
Phenomenex LUNA column (2.6 µ, C18, 100 Å, 4.6 × 100 mm) and a Phenomenex Security 
Guard precolumn (Luna C5 300 Å) for reverse-phase chromatography. UV absorbance was 
detected between 200 – 400 nm using the Waters 2998 diode array detector. Mass 
spectrometry data was calculated using the Waters Quattro Micro spectrometer, for detecting 
an m/z (mass/charge) range between 150 and 800 Da in positive (ES+) and negative (ES-) 
mode. 
The gradient elution conditions were; A, HPLC grade H2O containing 0.05% formic acid; B, 
HPLC grade CH3CN containing 0.045% formic acid) with the following program: 0 minutes, 
20% B; 15 minutes, 90% B; 16 minutes 95% B; 17 minutes 95% B; 18 minutes 10% B, 20 
minutes 10% B. Flow rate was set at 1 mL min-1. The data were acquired using Waters 




2.3.5 Preparative High-performance liquid chromatography (HPLC) analysis 
The preparative HPLC was carried out to detect a specific metabolite from a fungal crude 
extract.  The HPLC system was the same one used in the LC-MS analysis, but the separation 
and quantitation have been done on a Phenomenex LUNA column (5µ, C18, 100 Å, 10 × 250 
mm). The mobile phase was prepared by mixing a gradient of solvents (A, HPLC grade H2O 
containing 0.05% formic acid; B, HPLC grade CH3CN containing 0.045% formic acid). The 
elution program was performed with 0 minutes, 5% B; 2 minutes, 10% B; 20 minutes, 90% 
B; 21 minutes 95% B; 26 minutes 95% B; 27 minutes 5% B, 30 minutes 5% B, with flow rate 
at 16 mL/min. The injection volume was 20 μL. The UV absorbance was set at 200-400 nm 
and detected with a Waters 2998 diode array detector, while mass range from 100-600 Da in 
positive (ES+) and negative (ES-) mode was detected by a Waters Quattro Micro 




The sequence data of all the genes worked in this project were visualised through Benchling 
software. Primers design and selection of enzymes for the restriction digestion reaction were 
also done by this program. The program also allows to plan and design the expression vector 
for the Golden Gate cloning and the cloning reaction to build the recombinant plasmids. All 




Chapter 3 New promoters for improving pleuromutilin 
production in Aspergillus oryzae 
 
3.1 Introduction  
3.1.1 Biosynthetic evolution of pleuromutilin / production 
Ongoing problems with antibiotic resistance in the 1980s led to numerous drug derivatives 
being licensed from the existing antibiotic classes (Alanis, 2005). However, the issue of 
cross-resistance between the drugs of the same class continued to increase (Novak, 2011). 
The worst example came from the third generation of cephalosporins, where resistance was 
found in 1983, showing that SHV-2 enzyme was capable of hydrolysing these drug classes 
and this resistance spread rapidly (Kliebe et al., 1985, Knothe et al., 1983, Philippon et al., 
1989). Pleuromutilins have regained attention as a class of antibiotics following recent 
extensive biological and chemical characterisation. Many attempts have been made to 
improve and develop their antibacterial activity and the first pleuromutilin antibiotic for 
human use, retapamulin, made its way onto the market for topical use in humans for the 
treatment of skin infections like impetigo in 2007 (Jacobs, 2008).   
Pleuromutilin and its derivatives are known for an antibacterial activity against gram-positive 
cocci bacterial, such as Staphylococcus aureus, Streptococcus haemolyticus, and Bacillus 
subtilis (Kilaru et al., 2009). Further study also showed that the compounds were not only 
active against gram-positives but also active against gram-negative species such as 
Mycoplasma spp (Novak, 2011). Pleuromutilin has a unique mode of action via an interaction 
with the 50S ribosomal subunit, which inhibits prokaryotic protein synthesis. This make the 
drug attractive for further development as an antibiotic for human use (Shang et al., 2014).  
The approval process for pleuromutilin was very slow because it faced numerous problems 
around its metabolic instability, cardiac and hepatotoxicity concerns and insufficient oral 
bioavailability. Together these issues made it very challenging for product development and  
can explain why it had a poor perception in the pharmaceutical industry and resulted in a very 
slow progress in its development (Novak, 2011).  
In the last two decades, successful efforts in the development of semi-synthetic pleuromutilin 
drugs for human use were made by GSK (retapamulin, Figure 12 A-B) and Nabriva 
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Therapeutics (BC-3781 or lefamulin, Figure 12 C-D) (Prince et al., 2013, Rittenhouse et al., 
2006). These semisynthetic compounds were established through the extensive focus on SAR 
studies, along with the previous reports that pointed out that the nature of the C14 side chain 
could be an important key to determine its systemic efficiency (Egger and Reinshagen, 1976). 
Other reports have illustrated the correlation between C14 side chain and its impact on 
absorption, distribution, metabolism, excretion and toxicity (ADMET) parameters (Novak 
and Shlaes, 2010). In late 2006 lefamulin (Figure 12C), a thioether compound was first 
synthesized by Nabriva Therapeutics in two dosage forms: oral and intravenous (Figure 
12D). In 2011, it was the first systemic pleuromutilin to be tested successfully in clinical 
phase II trials. In August 2019, lefamulin (XenletaTM) was approved by FDA to treat 
Community-acquired bacterial pneumonia (CABP) in adult. It is the first systemic 
pleuromutilin antibiotic to have been launched into the market for IV and tablet use. (Press 




Figure 12 A) Chemical structure of retapamulin B) Topical ointment form of retapamulin 
launched in the market C) Chemical structure of lefamulin D) Tablets and injection dosage 




Since lefamulin is recently approved and launched into the market in both oral and 
intravenous dosages, this might lead to an increasing demand for the antibiotic in the future. 
One constraint on its use is that the commercial cost is high due to its low yield and 
semisynthetic modifications. The company announced that the injectable version would cost 
$205 per day, while the oral version would be $275 per day (Saumya, 2019). Pleuromutilin is 
a tricyclic compound that is naturally produced by C. passeckerianus, but due to its difficulty 
to grow under normal laboratory conditions, it usually requires a long period of fermentation 
and produces a very low titre (Nagamine et al., 2019). Therefore, seeking a strategy to 
increase the titre of pleuromutilin production for mass fermentation is urgently needed. 
The genetic techniques for transformation and gene manipulation for basidiomycetes have 
already been developed and reported (de Mattos-Shipley et al., 2011, Kilaru et al., 2009). 
Further study on characterization of genes responsible for pleuromutilin biosynthesis pathway 
was done by Bailey and Foster’s group (Bailey et al., 2016). The λ-phage genomic DNA 
library of C. passeckerianus was screened and the expression analysis has illustrated that -
GGS, Cyclase, P450-1, P450-2, P450-3, ATF and SDR were the seven genes responsible for 
pleuromutilin synthesis. The result was proven by the heterologous expression of the seven 
genes in the secondary host, A. oryzae giving production of pleuromutilin. Surprisingly, A. 
oryzae transformant strains containing the seven genes of pleuromutilin synthesis showed a 
significant increase of yield for pleuromutilin production compared to the natural host C. 
passeckerianus. 
Alberti et al., (2017), showed that silencing of the genes in C. passeckerianus to determine 
the function of each gene in the pathway was not a suitable method. Once a single gene in the 
cluster was silenced, it triggered the downregulation of the other genes involved in the 
pleuromutilin pathway and led to no accumulation of any intermediates that could be 
detected. In order to investigate the role of each gene, the heterologous expression of genes in 
A. oryzae and chemical analysis for an intermediate product were employed. Based on these 
results, levels of GGS and cyclase were the likely bottleneck for the pleuromutilin 
biosynthetic pathway. The expression of these two genes would control the entry of the main 
precursor into the pathway.  
Geranyl-geranyl diphosphate synthase (GGS) was demonstrated to be responsible for 
production of the precursor geranyl geranyl diphosphate (GGPP). Following that, cyclase 
(CYC) would catalyse the cyclization of GGPP. The expression of these two genes resulted 
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in the production of the first pathway intermediate, 3-deoxo-11-dehydroxy-mutilin (Figure 
13). This compound was the first committed step in the pleuromutilin biosynthesis pathway. 
The cytochrome P450s were proved to be involved in the pleuromutilin pathway. Their key 
role was to introduce modifications into the core structure of pleuromutilin. P450 enzymes 
are well known as a large group of enzymes that are commonly found in secondary 
metabolite biosynthesis pathway of bacteria, fungi and plants. These enzymes generate the 
complexity in the core structure by various reactions for example; oxidation, dehydration, 
epoxidation, C-C cleavage and etc (Hu et al., 2011, Lin et al., 2014, Seki et al., 2008). In the 
pleuromutilin biosynthesis cluster, there are three P450 genes: P450-1, P450-2 and P450-3, 
which were proved to be involved in the pathway. The P450-1 and P450-2 acted first by 
introducing the hydroxyl groups on C11 and C3 of the scaffold respectively (Figure 13).  
During the later stages of the pleuromutilin pathway, the short-chain 
dehydrogenase/reductase (SDR) was discovered to catalyse and convert the hydroxyl group 
at C3 into a ketone group.  Subsequently, acetyl transferase (ATF) was determined to be a 
part of the pathway, adding the acetyl group to the mutilin core at C14 to yield the last 
intermediate of the pathway, 14-O-acetyl mutilin. The final step was done by the action of 
P450-3 with a hydroxylation reaction to introduce a hydroxyl group on C22, converting the 
14-O-acetyl mutilin intermediate to the complete structure of pleuromutilin (Alberti et al., 
2017). Even though the heterologous expression in A. oryzae strains harbouring the seven 
genes of pleuromutilin biosynthesis pathway was successful, the total yield was still lower 
than expected and not suitable for mass production.  
In addition, the Alberti et al. (2017) study also performed a feeding experiment to explore the 
hypothesis that feeding the engineered A. oryzae stains with synthetic intermediates would 
provide the opportunity to gain a high efficiency of semisynthetic precursor conversion into 
other new intermediates. This could be a chance to reduce the number of steps involved in the 
semisynthetic process that is currently employed in pleuromutilin production. The results 
demonstrated that this was successful, but the yield was still very limited (Alberti et al., 
2017).  
The Alberti et al., (2017) study also indicated that the poor yield might due to the use of the 
enolase promoter to drive the expression of genes Cyclase, P450-3 and SDR within the 
pathway. This promoter showed the lowest expression level out of the three promoters (Padh, 
Pgpd and Peno) and thus may be a rate limiting step. In other words, the limitation of the 
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power of enolase promoter could lead to insufficient levels of Cyclase, P450-3 and SDR, 
thereby constraining yield of the final product. Therefore, an attempt to increase the titre of 























Figure 13 A) The seven genes involved in the pleuromutilin biosynthesis pathway B) Proposed biosynthetic pathway of pleuromutilin showing 






















The aim of this chapter was to enhance the production of pleuromutilin in the secondary 
fungal host Aspergillus oryzae. Feeding experiments with synthetic intermediates were also 
performed with semisynthetic intermediates to find new compounds that have better 
antibiotic activity.  
 
In order to complete the aim, several objectives were set as listed below: 
 
1. To recreate the expression vectors by replacing the enolase promoter activity involved 
in the efficient expression of the genes responsible for the biosynthesis of 
pleuromutilin in the secondary host A. oryzae 
2. A. oryzae transformation for the heterologous expression of the new expression 
vectors  
3. Preliminary bioassay screening against Bacillus subtilis for antibiotic activity of A. 
oryzae transformant strains 
4. Feeding experiments using A. oryzae transformant strains with a semisynthetic 
intermediate, to assess the capability of gene under control of the pdc promoter in 
order to convert the substrate to a desired compound 
5. Chemical analysis to evaluate yield improvement in the production of the metabolite 
extracted from A. oryzae transformant strains under the control of new promoter 













3.3.1 Promoter replacement to alter heterologous gene expression in A. oryzae 
The previous studies within our group showed fairly low titres of pleuromutilin production 
from A. oryzae, and the results indicated that weak expression from genes under the control 
of the enolase promoter might be rate-limiting. Therefore, my study was to identify better 
promotors to see if higher titres could be obtained by enhancing the expression of these 
genes. 
 
For efficient expression in A. oryzae, it is essential that the expression of the target gene be 
driven by an active promoter either derived from the host or a related species. Various 
promoters of A. oryzae have been reported for efficient recombinant protein production 
(Nevalainen and Peterson, 2014).   
The expressed sequence tag (EST) database analysis of A. oryzae (Akao et al., 2007, Wang et 
al., 2010) was used as a source for the candidate promoters of A. oryzae for my project, 
selecting the most abundantly expressed genes under liquid growth. Promotors chosen were; 
ptrA gene for thiamine thiazole synthase, an enzyme that is involved in thiamine 
biosynthesis, pgkA gene for phosphoglycerate kinase, involved in the glycolysis pathway 
which synthesizes pyruvate from D-glyceraldehyde 3-phosphate, and pdcA gene for pyruvate 
decarboxylase, an enzyme that converts pyruvate into acetaldehyde and carbon dioxide. 
These promoters were predicted to have strong activity in A. oryzae for the expression of 
foreign genes in liquid culture. Before using these promoters with the desired pathway genes, 
the expression of each promoter was investigated for its ability to drive expression of the 





















Figure 14 Principle of promoter expression cassettes. Promoter expression cassettes consist 
of a promoter of choice (ptr, pgk and pdc), reporter gene (GFP) and a selectable 
transformation marker (argB as auxotrophic host).  
 
First, yeast homologous recombination was performed in order to build this plasmid and 
insert argB into the backbone pYES2. The argB genes was amplified through PCR reaction 
with regions of 30 bases homology to the target backbone, by using specific primers. Yeast 
homologous recombination was performed to join the gene with the backbone plasmid, which 
had been previously digested with the restriction enzyme HindIII. Afterwards, the 
pYES2argB backbone was cut with the restriction enzyme NotI. Then another yeast 
homologous recombination was carried out in order to recombine the promoter and GFP gene 





3.3.2 Adapting pYES2 plasmid for A. oryzae transformation 
The pYES2 plasmid was first adapted with argB so it could be used in A. oryzae, then the 
selected promotor and GFP were recombined in (see principle in Figure 14). 
Yeast homologous recombination was carried out in order to build the plasmid pYES2argB 
(Figure 15A) by inserting argB gene into the backbone pYES2. The argB gene was amplified 
through PCR reactions, by using the primer pair ArgB FF*/ArgB RR* and the plasmid 
pTYGSarg was utilised as a template. Yeast homologous recombination was performed to 
merge the gene together along with the backbone plasmid, which had been previously 
digested with the restriction enzyme HindIII. All yeast colonies from the transformation plate 
were pooled, plasmid DNA extracted and transformed into E. coli. The plasmids obtained 
from E. coli were checked by PCR for the presence of the argB genes, with the same primers 
used to amplify the genes for yeast homologous recombination. The expected band of 1.5 kb 
was amplified from each sample. Correct construction of the plasmid was also confirmed 














Figure 15 A) Plasmid map of the expression vector pYES2argB. This plasmid was built 
starting from the backbone pYES2. B) Restriction digest showing correct construction of 
plasmid pYES2argB. Lane 1 contains 5 μL of hyperladder I (Bioline). Lane 2 contains 10 μL 
of digestion reaction with restriction enzyme PstI of pYES2argB (expected fragments 3.8 kb, 
3.1 kb and 488 bp). Lane 3 contains 1 μL of undigested plasmid DNA of pYES2argB. 
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To confirm that the pYES2argB vector was functional, A. oryzae was transformed with the 
plasmid pYES2argB, which contains the argB gene as a selectable marker. At least five 
transformant colonies were obtained and subcultured onto selective medium for two 
consecutive times. The gDNA of each transformant was extracted with the rapid DNA 
extraction method. A PCR was performed using specific pairs ArgB FF*/ArgB RR* directed 
towards the argB gene. The argB fragment was amplified from all five A. oryzae 
transformants containing pYES2argB. It could be clearly demonstrated that the pYES2argB 
vector was suitable as a backbone for the insertion of promoter-GFP genes. 
 
3.3.3 Plasmid construction for expressing GFP under the control of various A. oryzae 
promoters 
Three plasmids for the expression of GFP were constructed: 1) ptr-GFP carried 0.7 kb ptr 
promoter followed by 0.7 kb GFP, 2) pgk-GFP that carried 0.5 kb pgk promoter followed by 
0.7 kb GFP, and 3) pdc-GFP carried 0.5 kb pdc promoter followed by 0.7 kb GFP.  
Yeast homologous recombination was carried out in order to build this plasmid and insert 
promoter and GFP gene into the backbone pYES2argB. The ptr promoter and GFP genes 
were amplified through PCR reactions, by using the primer pair ptrA FF(1)*/ ptrA RR(1) and 
prtA/GFP FF(2)/ ptrA/GFP RR(2)*, the pgk promoter and GFP genes were amplified by 
utilising the primers pgkA FF(1)*/ pgkA RR(1) and pgkA/GFP FF(2)/ pgkA/GFP RR(2)* 
and the pdc promoter and GFP genes were amplified through primers pdcA FF(1)*/ pdcA 
RR(1) and pdcA/GFP FF(2) pdcA/GFP RR(2)*. High-fidelity PCR amplification was carried 
out using the gDNA of A. oryzae NSAR1 as a template. Yeast homologous recombination 
was performed to merge the promoter fragment and GFP fragment together along with the 
backbone plasmid, which had been previously digested with the restriction enzyme NotI. All 
colonies from the transformation plate were pooled, plasmid DNA extracted and transformed 
into E. coli. The plasmids obtained from E. coli were checked with PCR for the presence of 





As a result, three out of twenty-eight transformant colonies showed the successful construct 
of pYES2arg/ptr-GFP plasmid. Correct construction of pYES2argB/ptr-GFP plasmid (Figure 













Figure 16 A) Plasmid map of the expression vector pYES2argB/ptr-GFP with GFP gene 
under control of ptr promoter. B) Restriction digest showing correct construction of plasmid 
pYES2argB/ptr-GFP: Lane 1 contains 5 μL of hyperladder I (Bioline). Lane 2 contains 10 μL 
of digestion reaction with restriction enzyme BamHI of pYES2argB/ptr-GFP (expected 













Three out of fifty-six transformants colonies showed the successful inserted pgk promotor 
and GFP gene. Correct construction of pYES2argB/pgk-GFP plasmid (Figure 17A) was 















Figure 17 A) Plasmid map of the expression vector pYES2argB/pgk-GFP with GFP gene 
under control of pgk promoter. B) Restriction digest showing correct construction of plasmid 
pYES2argB/pgk-GFP: Lane 1 contains 5 μL of hyperladder I (Bioline). Lane 2 contains 10 
μL of digestion reaction with restriction enzyme PstI of pYES2argB/pgk-GFP (expected 













Two out of thirty transformant strains showed the successful construct of pYES2argB/pdc-
GFP plasmid. Correct construction of pYES2argB/pdc-GFP plasmid (Figure 18A) was 














Figure 18 A) Plasmid map of the expression vector pYES2argB/pdc-GFP with GFP gene 
under control of pdc promoter. B) Restriction digest showing correct construction of plasmid 
pYES2argB/pdc-GFP: Lane 1 contains 5 μL of hyperladder I (Bioline). Lane 2 contains 10 
μL of digestion reaction with restriction enzyme PstI of pYES2argB/pdc-GFP (expected 
fragments 3.8 kb, 3.1 kb, 1.2 kb and 488 bp).  Lane 3 contains 1 μL of undigested plasmid 










3.3.4 Transformation of A. oryzae to investigate the expression levels of GFP under the 
control of various promoters 
 
The transformation of A. oryzae (strain NSAR1) with plasmid pYES2argB/ptr-GFP, 
pYES2argB/pgk-GFP and pYES2argB/pdc-GFP were made separately in order to assess 
expression of the GFP under the control of different promoters. The transformant colonies 
were obtained and subcultured onto selective medium for two consecutive times. 
Fluorescence of stable transformants were observed under fluorescence microscope, and the 
transformants containing pYES2argB with no GFP were used as a negative control (figure 
not shown). From five transformants of pYES2arg/ptr-GFP only one strain showed the 
expression of GFP in their mycelia (Figure 19A). While two out of five transformants of 
pYES2arg/pgk-GFP showed the GFP expression (Figure 19B).  Five out of ten transformants 
of pYES2arg/pdc-GFP showed a strong fluorescence expression (Figure 19C). The 
transformant colonies containing pYES2arg/pdc-GFP showed the stronger expression of GFP 
in their mycelia when compared with the transformant colonies contain pYES2argB/ptr-GFP 
and pYES2argB/pgk-GFP. Therefore, the pdc promoter was chosen to use as a new promoter 
to replace and drive the genes that previously under the control of eno promoter in the 












Figure 19 Fluorescence of GFP in the hyphae of representative A. oryzae transformants. A) 
pYES2argB/ptr-GFP vector. B) pYES2argB/pgk-GFP vector. C) pYES2argB/pdc-GFP 
vector. 
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3.3.5 Construction to recreate the three new plasmids under the control of pdc 
promoter for Cyclase, P450-3 and SDR genes 
 
There were three genes under the control of the enolase promoter (Peno) in the previous 
expression vectors: Cyclase, P450-3 and SDR, (Table 5 indicated in red). Their expression 
vectors were redesigned to replace Peno with the pdc promoter. Using the yeast 
recombination method, pTYGSargGGSCyclase, pTYGSadeP1P2P3 and pTYGSbarATFSDR 
were used as backbones and were cut with SpeI. The pdc promoter region for driving 
expresion of Cyclase, P450-3 and SDR was amplified using primer pair; pdcA-CYC FF*/ 
pdcA-CYC RR*, pdcA-P450-3 FF*/ pdcA-P450-3 RR* and pdcA-SDR FF*/ pdcA-SDR 
RR* for each gene, respectively. The correct construction of three new vectors: 
pTYGSargGC-Ppdc, pTYGSadeP1P2P3-Ppdc and pTYGSbarAS-Ppdc was confirmed by 
PCR for the presence of the pdc fragment. Restriction digestions with appropriate enzymes 
were also done to confirm the correct assembly (Figure 20). 
 
Table 5 Details of the previous plasmids used by Dr. Alberti to express the seven genes of 
the pleuromutilin pathway in A. oryzae. Selective markers; argB - Ornithine 
carbamoyltransferase, adeA -gene which encodes purine biosynthesis and bar - 
Phosphinothricin acetyl transferase gene. Promoters; adh -Alcohol dehydrogenase, gpdA - 
Glyceraldehyde-3-phosphate dehydrogenase and eno -enolase. 
 























































Figure 20 Predicted maps and confirming digests: Illustrating correct assembly of the new 
pleuromutilin plasmids with A-B) Cyclase, C-D) P450-3 and E-F) SDR under control of the 
pdc promoter. Lane 1 contains 5 μL of 2-log ladder. Lane 2 contains 10 μL of digestion 
reaction with restriction enzyme. Lane 3 contains 1 μL of undigested plasmid DNA. 
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3.3.6 A. oryzae transformation with pTYGSarg/GC-pdc 
The pdc promoter was chosen to drive Cyclase expression which was previously under the 
control of the eno promoter. It was predicted that the pdc promoter would lead to the better 
expression of Cyclase gene, so expression of GGS together with pdc-Cylcase should provide 
a higher accumulation of the 3-deoxo-11-dihydroxy-mutilin (metabolite 1), the first 
intermediate of the pleuromutilin biosynthesis pathway. 
The plasmid, pTYGSargGC-Ppdc was used to transform A. oryzae NSAR1 for heterologous 
expression. After subculture three times, seven stable transformant strains named as A. oryzae 
GC-Ppdc TS2- (1-7) were generated from the transformation. Successful transformation of 
pTYGSarg/GC-Ppdc was confirmed through PCR amplification for the presence of Ppdc-
Cyclase (Figure 21).  All the A. oryzae GC-Ppdc TS2- (1-7) transformant strains were 












Figure 21 Gel electrophoresis showed PCR amplification of Ppdc-Cyclase (expected 
fragment 3380 bp) from gDNA extracted from A. oryzae GC-Ppdc transformant strains TS2- 
(1-7). Lane 1 contains 5 μL of 2-log ladder. Lane 2-8 gDNA of A. oryzae transformant strain 
was used as template. Lane 9 the same plasmid used for transformation was used as template. 






3.3.6.1 Bioassay screening for antibiotic activity of A. oryzae GC-Ppdc genes 
transformant strains 
Preliminary screening for antibacterial activity of the seven A. oryzae GC-Ppdc TS2- (1-7) 
were done against B. subtilis. The engineered strains were cultured separately on CMP agar 
plates for 3 days. Then TSAg containing B. subtilis and TTC was used to overlay around the 
fungal colony to develop a clearing zone to detect if any antibiotic was being produced. The 
plates were incubated overnight at 28oC and the next day they were examined to see if any 
inhibition zone was present and zones were measured. Plate-based assay showed that A. 
oryzae GC-Ppdc TS2-2 had the strongest antibacterial activity with the largest clearing zone, 
while A. oryzae GC-Ppdc TS2- 4, 3 and 6 also demonstrated antibacterial activity. No 
clearing zone could be observed from A. oryzae GC-Ppdc TS2- 1, 5 and 7 (Table 6). 
Transformant TS2-2 only gave a zone of 2-3mm, so antibiotic activity was comparatively 
weak as would be expected from a pathway intermediate. 
 
Table 6 Results of the bioassay screening for antibacterial activity of A. oryzae GC-Ppdc 
TS2- (1-7) against B. subtilis. 
 
Sample 
Results of the bioassay screening for 
antibacterial activity against B. subtilis 
A. oryzae NSAR1  
A. oryzae GC-Ppdc TS 2-1  
A. oryzae GC-Ppdc TS 2-2  
A. oryzae GC-Ppdc TS 2-3  
A. oryzae GC-Ppdc TS 2-4  
A. oryzae GC-Ppdc TS 2-5  
A. oryzae GC-Ppdc TS 2-6  









3.3.6.2 Chemical analysis of A. oryzae strains containing pTYGSarg/GC-Ppdc for 
production of 3-deoxo-11-dehydroxymutilin (metabolite 1) 
The three transformant strains of A. oryzae GC-Ppdc TS2- 2, 3 and 4 were progressed 
through chemical analysis. The spores of each transformant were cultured in 100 mL CMP 
for 10 days. The cultures were then extracted with ethyl acetate. After that the crude extracts 
were analysed for the presence of metabolite 1 to confirm the activity of GGS and Cyclase-
Ppdc using Thin layer chromatography (Figure 22). It was shown that all three transformant 
strains were producing metabolite 1, so confirming the activity of GGS and Cyclase. In term 
of apparent yield, the spot of TS2-2 presented a slightly stronger accumulation of metabolite 
1 than the others transformant strains, including TR5, where Cyclase was driven under Peno. 
Thus, it could be concluded that the expression of the Cyclase under the stronger pdc 














Figure 22 Thin layer chromatography demonstrated the presence of metabolite 1 from A. 
oryzae GC-Ppdc TS2- 2, 3 and 4 when compared with A. oryzae WT (WT) and A. oryzae GC 







3.3.7 A. oryzae GC-pdc transformation with pTYGSade/P1/P2/pdc-P3 (generation of 5 
genes transformant strains) 
From the previous transformation and chemical analysis, A. oryzae GC-pdc TS2-2 produced 
the most metabolite 1, so was the strain was chosen for the second round of transformation 
with pTYGSade/P1/P2/pdc-P3 plasmid, to create a five-gene transformant strain. Five 
independent transformant strains were generated from the second transformation and were 
named as A. oryzae GC-pdc/P1P2P3-pdc TS5- (1-5). The stable and correct transformants 
were tested by PCR amplification to assess the presence of Ppdc-P450-3 (Figure 23). All 










Figure 23 Gel electrophoresis of PCR amplification of Ppdc-P450-3 (expected fragment size 
of 2069 bp) from gDNA extracted from A. oryzae P1P2P3-Ppdc transformant strains TS5- (1-
5). Lane 1 contains 5 μL of 2-log ladder. Lane 2-6 gDNA of A. oryzae transformant strain 
was used as template. Lane 7 the same plasmid used for transformation was used as template. 
Lane 8 water was used as negative control. 
 
 
3.3.7.1 Bioassay screening for antibiotic activity of A. oryzae 5 genes transformant 
strains  
The plate-based bioassay against B. subtilis was used to determine an antibiotic activity from 
A. oryzae 5-gene transformant strains. The assay was carried out by culturing each A. oryzae 
GC-pdc/P1P2P3-pdc TS5- (1-5) on CMP agar plates at 28oC for 3 days. Then the 
transformant colonies were overlaid with TSAg containing B. subtilis and TTC. After 
overnight incubation at 28oC, clearing zones were observed and measured to confirm an 
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antibiotic activity. The bioassay screening for antibiotic activity of A. oryzae GC-
pdc/P1P2P3-pdc TS5- (1-5) showed that TS5- 1, 3, 4 and 5 had a weak antibiotic activity, 
while there was no clearing zone observed for TS5-2 (Table 7).  
 
Table 7 Results of the plate-based antibiotic bioassay of A. oryzae 5-gene transformant 
strains against Bacillus subtilis. 
 
Sample 
Results of the plate-based bioassay against 
Bacillus subtilis to test antibiotic activity 
A. oryzae NSAR1  
A. oryzae GC-pdc/P1P2P3-pdc TS 5-1  
A. oryzae GC-pdc/P1P2P3-pdc TS 5-2  
A. oryzae GC-pdc/P1P2P3-pdc TS 5-3  
A. oryzae GC-pdc/P1P2P3-pdc TS 5-4  
A. oryzae GC-pdc/P1P2P3-pdc TS 5-5  
 
 
3.3.7.2 Chemical analysis of A. oryzae 5 genes transformant strains for pleuromutilin 
A. oryzae GC-pdc/P1P2P3-pdc TS5-3 and TS5-4 were chosen and progressed through 
chemical analysis for metabolite extraction. Spores of A. oryzae GC-pdc/P1P2P3-pdc TS5-3 
and TS 5-4 were cultured in 100 mL CMP and incubated with shaking at 28oC for 10 days. 
The culture was extracted with ethyl acetate and the crude extract was analysed by TLC for 
metabolite production. The TLC analysis of the extracts from A. oryzae TS5-3 and 5-4 
(Figure 24) showed the accumulation of two candidate pleuromutilin intermediates. The first 
compound with high mobility, indicated in the upper red box, was suspected to be metabolite 
1, the product of GGS and Cyclase. The second compound with lower mobility indicated in 
the lower red box was suspected to be either the 3-deoxo-mutilin (metabolite 2) resulting 
from the expression of GGS, Cyclase and P450-1 or the 3-dihydro-mutilin (metabolite 3), 
which would result from the expression of GGS, Cyclase, P450-1 and P450-2, or it could be a 
new metabolite. The results also illustrated the likely incomplete conversion of metabolite 1 
to the next intermediate of the pathway. However, these results still support the hypothesis 
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that metabolite 1 structure was modified by the addition of the P450 genes.  These genes are 
responsible for introducing hydroxyl groups to the pleuromutilin scaffold, resulting in a 
higher polarity of the molecule, so a compound with reduced mobility on TLC would be 














Figure 24 TLC analysis of the extract from A. oryzae transformant strains containing 5 genes 
showed the accumulation of suspected metabolite. From left to right; WT= A. oryzae NSAR1 
wild type, 1 = A. oryzae GC-pdc strain TS2-2, 2 = A. oryzae GC-pdc strain TS2-3, 3 = A. 















3.3.8 Feeding experiment of A. oryzae strains contain pTYGSade/P1P2P3-pdc with 14-
O-acetyl-mutilin 
Khairudin (Khairudin, 2018) had previously shown that non-acetylated mutilin derivatives 
could be fed to A. oryzae expressing P450-3 and ATF and could be modified accordingly. 
However, the P450-3 step was often poor or incompletely achieved. Therefore, the new 
transformants with P450-3 under regulation of the pdc promoter were evaluated to see if they 
could overcome this problem. 
A. oryzae transformants with P1P2P3-pdc TS3- (1-6) were cultured at 28oC for 10 days in 
100 mL CMP which was supplemented with 14-O-acetyl-mutilin, the synthetic intermediate 
kindly provided and synthesized by Jonathan Davies, School of Chemistry, University of 
Bristol. The cultures were chemical extracted with ethyl acetate, and crude extracts were 
analysed through HPLC for the production of pleuromutilin (Figure 25). The HPLC showed 
presence of the substrate in all samples. Transformants 2, 3 and 6 had a weak but detectable 
peak at 11.95 min characteristic for pleuromutilin, but the conversion was very inefficient 























Figure 25 The ELSD chromatograms of standard compounds compared with A. oryzae WT and crude extracts from A. oryzae P1P2P3-pdc 




The work described in this chapter aimed to improve the pleuromutilin production by 
heterologous expression of the pleuromutilin biosynthesis pathway in the secondary fungal 
host, Aspergillus oryzae. The strategy was to enhance the expression level of the promoter 
that drive the genes within the cluster. In addition, I set out to assess whether synthetic 
compounds fed to A. oryzae transformant strain could be an efficient route to obtain new 
derivatives or compounds with more potent antibiotic activity. 
The genes under the control of enolase promoter (Peno) were previously shown to have weak 
expression compared with other genes under the control of alcohol dehydrogenase (Padh) 
and glyceraldehyde-3-phosphate dehydrogenase (Pgpd) promoters (Alberti et al., 2017). 
Therefore, the low amount of one enzyme might result in the low level of other substrates and 
limit the final product to be obtain from the pathway. It was also hypothesised that the 
enzymes participating in pleuromutilin biosynthesis pathway might act as a multienzyme 
complex, which means that the product from one enzyme might channel directly to other 
enzymes along the pathway, and if one protein was in limiting amount, it might prevent 
correct assembly of the entire enzyme complex. To replace the enolase promoter with a 
stronger promoter is a hypothesis to improve the levels of gene expression and so overcome 
either of these limitations. 
For this project, the candidate for a new promoter to replace Peno was chosen based on the 
expressed sequence tag (EST) database analysis of A. oryzae (Akao et al., 2007, Wang et al., 
2010). Thiamine thiazole synthase (ptrA), phosphoglycerate kinase (pgkA) and pyruvate 
decarboxylase (pdcA) were the three promoters that were selected due to their plentiful 
expression in liquid culture compared to the enolase promoter (Wang et al., 2010). With the 
expectation that these promoters would have a great potential and strong activity in A. oryzae 
for the expression of a foreign gene, the investigation of each promoter’s expression was 
done by assessing the GFP reporter gene expression. As a result, the pdc promoter showed 
the strongest expression of GFP from the mycelia of a stable A. oryzae transformant when 
observed under the fluorescence microscope. Similar results from the EST library also 
supported the high expression of pdc promoter. The cDNA library from A. oryzae mycelia 
was constructed, which each clone was made from 3’ region of mRNA and the result showed 
that out of 345 randomly selected clones, pdc had the highest level of expression (Hwang et 




Therefore, the pdc promoter was chosen to use as a new promoter to replace Peno and drive 
the genes in the pleuromutilin biosynthesis pathway. Yeast recombination was used as a 
method to replace Peno with Ppdc. Three new plasmids: pTYGSarg/GC-pdc, 
pTYGSade/P1P2P3-pdc and pTYGSbar/AS-pdc were constructed, the Cyclase, P450-3 and 
SDR genes were now under the control of the pdc promoter that was expected to deliver 
better expression. The first plasmid, pTYGSargGC-pdc, was made and transformed into A. 
oryzae NSAR1 WT.  Although not fully quantified, TLC of crude extract from A. oryzae GC-
Ppdc TS2-2 suggested an increase in production of metabolite 1 compared with the previous 
A. oryzae GC transformant used by Alberti et al., (2017). It is assumed that the expression of 
Cyclase was better under the control of pdc promoter although this was not quantified. Other 
report have also showed the potential of the pdc promoter for the expression of heterologous 
genes for example in Zymomonas mobilis, the resulted had shown that alaD gene was driven 
by the pdc promoter exhibited the double in expression than its natural alaD producer 
(Uhlenbusch et al., 1991). Unfortunately, the production of the expected metabolite 1 in this 
study was still limited given the expected strength of this promoter. Even though, the pdc 
promoter was shown to drive GFP effectively, it is worth highlighting that the 500 bp of the 
pdc promoter region used in this study might not include all of the necessary regulatory 
elements and perhaps a larger region would have supported stronger expression. 
Progression towards the complete pleuromutilin structure was achieved by introducing the 
pTYGSade/P1/P2/P3-pdc vector into the A. oryzae GC-pdc T2-2. The chemical analysis from 
the extracts of the 5 gene transformants showed the accumulation of two metabolites. One 
was suspected to be metabolite 1. The other one was suspected to be either the known 
intermediate metabolites 2 or 3, or a new metabolite. In order to confirm identity of these two 
compounds, a more sensitive separation technique such as liquid chromatography-mass 
spectrometry (LC-MS) is needed for detection. 
The final investigation was the feeding experiment to investigate the activity of P450-3 on 
fed substrates. By working together with the group from Chemistry, the A. oryzae 
transformant strains TS3- (1-6) containing pTYGSadeP1P2P3-Ppdc were use in feeding 
experiments with the synthetic intermediate 14-O-acetyl-mutilin and assessed for C22 
hydroxylation via LC-MS analysis. The hypothesis of this strategy is that the better 
expression of P450-3 under the control of pdc promoter could lead to better ability of P450-3 
to provide more effective conversion of 14-O-acetyl-mutilin to the final product, 
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pleuromutilin. A higher titre of pleuromutilin or finding a new compound that has a better 
antibiotic activity are also the expected result from this scheme. Unexpectedly, the 
conversion of 14-O-acetyl-mutilin to the final product, pleuromutilin by P450-3 under the 
control of pdc promoter was extremely poor. It had been predicted that good expression 
should result in better than 80% conversion (based on the approximately 50% conversion 
seen previously with the enolase promotor) and the reason for this lack of conversion is 
unclear. It should be noted that fewer than ten A. oryzae transformants were selected for 
chemical analysis in this study. Given that fungal transformation results in integration of the 
transforming DNA into the chromosomes, each transformant would likely have a different 
number of copies of the insertion, and at loci likely to give differing levels of expression. 
Therefore, the number of transformants being screened might not enough to find any 
effective production of an expected metabolites. To find a strain with a highly expressed gene 
to accumulate a compound, larger number of transformants would be needed to be screened. 
In order to get a more reliable result, around 20-30 positive transformants should be tested. 
It is possible that the feeding experiment was unsuccessful due to the growth conditions and 
the experiment assumes that the substrate is taken up by the fungus. The components of 
growth media such as carbon and nitrogen sources seem to be a strong influence on the 
physiology of the fungus and thus whether it is in a growth phase amenable for production of 
secondary metabolites (Bose et al., 2019). In order to maximise metabolite production or 
indeed activity of enzymes such as P450s, optimisation of culture media and culture 
conditions should be performed.  
Another potential concern is that basidiomycetes enzymes may not function properly in the 
ascomycete cytoplasm, so it is possible that the P450s were expressed efficiently, but were 
not being properly activated by the Aspergillus cytochrome P450 reductase (CPR) or perhaps 
not directed to the appropriate subcellular compartment (Nagamine et al., 2019). For a better 
understanding of what had happened, RNA-based analysis should be performed on the cDNA 
of each A. oryzae transformant strains to confirm efficient gene expression and perhaps 






3.5 Summary  
In conclusion, heterologous expression of selected genes of the pleuromutilin biosynthesis 
pathway in A. oryzae transformants strains was performed after replacing the enolase 
promoter with a stronger promoter, pyruvate decarboxylase. This did not deliver a higher titre 
of pleuromutilin pathway metabolites. A more flexible heterologous host system might be 
























Chapter 4. Feasibility of production of pleuromutilin in planta by 




Plants are well known as producers of compounds in the terpene family. Many of the scents 
made by flowers are often terpene or sesquiterpene based, for instance sandalwood and 
lavender (Guitton et al., 2010, Jones et al., 2011). The active ingredients of many herbs and 
spices used in cooking are also terpenes, e.g. basil, oregano and hops (Steenackers et al., 
2015, Yang et al., 2007). All higher plants have the ability to make diterpene compounds, for 
instance the phytohormone gibberellin is a diterpene, and is used in controlling cell 
expansion, involved in etiolation of shoots amongst other things (Hedden and Sponsel, 2015). 
From a medical perspective, there are also important plant-derived terpenes such as the 
sesquiterpene-based artemisinin, used in the treatment of malaria, produced by sweet 
wormwood Artemisia annua (Arsenault et al., 2008), or the diterpene taxol, a potent anti-
cancer drug, derived from the leaves of Taxus baccata, the common yew tree (Heinig and 
Jennewein, 2009). Given that plants are clearly capable of generating commercial levels of 
useful terpenes, this chapter set out to investigate whether it was feasible to engineer 
production of pleuromutilin into plants. Plants, being comparatively easy to grow, provide 
readily scalable production platforms which should allow the cost-effective, timesaving and 
efficient expression of products compared to traditional fermentation-based methods that 
require expensive equipment and have high energy requirements both for sterilising 
media/waste and for continual operation. Moreover, when compared with the outcomes from 
animal or microbial culture, the products generated from plant system are safer (no risk of 
human-infecting viruses), easier to produce and less expensive (Fischer et al., 2004). 
In recent years the ability to engineer plants has made some significant steps forward, mostly 
linked to engineering of crops. These typically only introduce one or two genes into the plant, 
often with protein products as their main aim and so are of limited use in engineering a multi-
step biochemical pathway. Numerous studies demonstrated that various proteins with 
therapeutic use such as complex antibodies and vaccines, were produced from the feasibility 
and advantages of plant-based production platforms. (Orzaez et al., 2006, Virdi and Depicker, 
2013). The release of “Golden rice” shows how engineering of novel metabolites can be 
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achieved in plants. Here rice was made to accumulate the yellow compound beta carotene, a 
precursor of vitamin A. This was achieved by heterologous expression of two genes, to 
convert host-derived geranylgeranyl pyrophosphate using phytoene synthase from daffodil 
and phytoene desaturase from the soil bacterium Erwinia, which, along with the hosts 
lycopene cyclase, gave low yields of beta carotene in the seeds (Ye et al., 2000). This was 
subsequently improved by (Paine et al., 2005) using the phytoene synthase from Maize 
giving higher yields. 
 
4.1.1 Plant-based systems for heterologous expression 
The majority of reports for plant biotechnology have required expression of just a few genes, 
which can be achieved using simple expression constructs. Even the example above of golden 
rice was only expression of two transgenes in addition to the selectable marker. The 
pleuromutilin pathway involves seven biosynthetic genes, all of which would be needed for 
successful expression (perhaps with the exception of GGS – although this is a pathway-
specific version in fungi). At the commencement of this project there were very few plant 
expression systems that would allow for easy construction of a seven-gene expression 
cassette. 
Assembly of multi-component constructs such as promoter, gene of interest and terminator 
expression cassettes is a general task for molecular research. Many methods have been 
developed and used over the years. Often each approach will work only for a particular 
cloning project due to time limitation, cost, availability of materials, size of construction and 
specific preferences of the project.  
Restriction enzyme cloning is a classic cloning method and remains one of the most general 
processes in everyday research. Based on digestion and ligation reaction by utilising enzymes 
that cut double stranded DNA into fragments which containing precise 5’ or 3’ single strand 
overhangs (sticky ends) or no overhang (blunt ends) in digestion reaction. The compatible 
DNA fragments that have complementary sticky or blunt ends then will be joined together in 
ligation reaction. This method is helped by the number of available enzymes, which also 
work for a specific target sequence, give a fully predictable result and also the price is 
relatively cheap. Unfortunately, it is a very time-consuming method and is not well suited for 
assembling a large number of fragments especially if the same region is present in several 
83 
 
places in the vector and also increasing the difficulty on an issue for PCR-based or yeast-
based assembly (Emami et al., 2013).  
Another popular recombination-based cloning exploiting the lambda phage’s integration and 
excision mechanism, which was invented and commercialised by Invitrogen as Gateway® 
Recombination Cloning. This strategy is done via a single recombination reaction, 
simplifying the process and reducing the time compared to restriction enzyme-based cloning. 
In brief, the fragment of DNA to be joined needs to be amplified and flanked by specific 
recombination sites, Gateway attB1, and attB2. The PCR amplification product then is mixed 
with a donor plasmid by the BP clonase enzyme mix to create an entry clone. The entry clone 
cassette can then be easily shuttled into any compatible Gateway® Destination vector through 
LP clonase enzyme mix (Figure 26). A typical Gateway destination vector system for gene 
expression contains multiple cloning sites, a variety of promoters and different selection 
cassettes, allowing the insertion of genes of interest. The version called MultiSite Gateway® 
allows the cloning of up to five different fragments. However, there are several drawbacks of 
the method; the cloning kit is rather high cost, the recombination site leaves so-called scars 
with 25 base pair of unwanted sequence that might be a problem for expression and even with 
the MultiSite version, the number of fragments is limited to five. Therefore, it is not a 
suitable approach for assembling the pleuromutilin gene cluster in this project (Lampropoulos 










Figure 26 Illustration of the Gateway cloning process. Image from Soriano, (2017). 
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The Gibson cloning method, also known as Isothermal cloning (Gibson, 2011), takes 
advantage of the T5 exonuclease enzyme property, which digests a double stranded DNA in 
the 5’-3’ direction to generate a DNA fragment with 3' single-stranded overhangs. DNA 
fragments that have 20-40bp of homology sequence at their ends are joined together (Figure 
27). The process is similar to restriction enzymes cloning but with greater in length of 
complementary sequence and no need to introduce cloning scars. Phusion DNA polymerase 
is used to fill in any remaining regions between the annealed DNA fragments and then the 










Figure 27 Outline of the Gibson cloning method. Image from Cutts and Vannini, (2018). 
 
The advantages of this method are: 1) it is fast, flexible and lower in cost compared with 
commercial systems such as Gateway®, 2) it allows for multiple fragments of DNA to be 
combined, typically up to five fragments in a single reaction or up to fifteen fragments in two 
steps, 3) DNA fragments can be joined without creating any unwanted DNA sequence at the 
junctions when compared with restriction enzyme or Gateway recombination cloning. 
However, this method also contains a number of weaknesses: 1) undesired side products can 
be produced due to the repeats of homologous region used to anneal DNA fragments, 2) a 
stable secondary structure of single-stranded DNA such as hair-pins will not be able to base 
pair with its target, 3) small fragments less than 250 base pairs might be completely digested 
by the exonuclease enzyme before the annealing process (Emami et al., 2013). 
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The Golden Gate cloning system is a method that provides an efficient assembly of a large 
numbers of DNA fragments and the whole process is claimed to be faster and easier 
compared to the other methods mentioned above. Based on a unique action of type IIS 
restriction endonuclease enzymes, which cleave DNA at a site outside of their recognition 
sites, this results in DNA fragments that have compatible four bases overhang that can be 
ligated scarlessly. This method provided a feasible scheme for directional assembly of 
multiple fragments. According to Weber et al., (2011), 11 transcription units made from 44 
basic fragments were successfully assembled and generated 33 kb construct via three 
successive one-pot cloning steps. Since the goal of this chapter is to clone the total 
pleuromutilin biosynthesis pathway into one expression vector, the Golden Gate cloning 
system appeared to be suitable to assemble multiple fragments, so was chosen as a tool to 
create the pleuromutilin expression vector for in planta use for this project. More detail of the 
Golden Gate cloning system will be described later in the results section of this chapter. 
The choice of plant species for the expression of heterologous genes is an important factor in 
the design of a plant-based production system. The selection of plant host depends on several 
criteria; the nature of secondary metabolite, available technology for gene transfer and 
expression, the ability for regeneration and post-translational modifications in the host, ability 
to scale-up production, cost for maintenance and the downstream processing requirements 
(Makhzoum et al., 2014). There are variety of plant crops types that have been tested and 
used for the commercial production of pharmaceutical proteins such as leafy crops, seed and 
legumes crops, oil crops and fruit and vegetable crops.  
Seed-based systems offer many advantages for example: providing a likelihood of long-term 
storage even at room temperature with no detectable loss of protein content, specific 
expression of transgene in seed has biosafety benefits as it will not affect other growth 
phases. However, the transgenic plants need to go through a flowering cycle to produce seed. 
This has issues for gene contamination and a chance of contamination through pollen transfer 
(Makhzoum et al., 2014, Rademacher et al., 2009). Several fruit and vegetable crops are 
being utilised for the production of recombinant vaccines and antibodies application, due to 
their advantage as edible plants that can be consumed directly. For instance, potatoes were 
chosen as a production system of rotavirus VP6 capsid protein to treat acute viral 
gastroenteritis (Yu and Langridge, 2003). But this platform is limited by the timing of 
ripening and harvesting, so production is seasonally dependent. 
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Leafy crops have major advantages in term of biomass yield, case of leaf harvesting that can 
be done without having a flowering cycle and thus also reduce contamination through pollen 
dispersal. Tobacco is one of the strongest candidates. It is a non-food crop, which will reduce 
the risk of contamination within human food chain (Twyman et al., 2003), it has high 
biomass yield, fast growth and easy harvesting all year round. It is ideal for transgene 
expression due to its long history as a plant-based system in molecular studies,  gene transfer 
and expression methods are well-established and a large-scale infrastructure for 
manufacturing already exists (Makhzoum et al., 2014). One disadvantage of tobacco is that it 
contains high levels of phenolic compounds, which may need to be removed as part of the 





The aim of the work described in this chapter was to recreate the pleuromutilin biosynthesis 
pathway in tobacco plants.  
 
This could be broken down into several stages: 
1. Choice of expression system to recreate the pleuromutilin biosynthesis pathway in tobacco    
    plants 
2. Making the plasmid construct containing the genes involved in the pleuromutilin  
    biosynthesis pathway   
3. Agrobacterium infiltration to generate transient N. tabacum plants expressing   
    the pleuromutilin biosynthesis pathway to validate the pathway 
4. Evaluate the phenotype development of infiltrated N. tabacum. If successful with transient  







4.3.1 Rationale for the choice of vector system and design of the expression construct 
To build an expression vector containing the seven genes involved in pleuromutilin 
biosynthesis and transform this into the secondary host, N. tabacum, various possible 
strategies were considered. 
Yeast-based methods were a possibility using the yeast-adapted pCambia plasmids developed 
within the group, however the existing vectors were made for fungal transformation and there 
were not enough different plant promoters and terminators that were already fully validated 
to be able to assemble all the genes in one construct. It would be possible to split them across 
two or three plasmids providing enough plant selectable markers were available, or to 
transform different plants with each, and then cross them to get the constructs into the one 
plant, however, this was considered to be overly time-consuming. 
A review of the literature identified that several technologies have been developed to allow 
assembly of multiple parts for biosynthetic pathway engineering in plants. For instance, the 
published Gateway methods allowed a few genes to be moved, but at the time of 
experimental design these were not readily available with plant expression cassettes and plant 
selectable markers in Agrobacterium-adapted systems, certainly not for the number of genes 
that needed to be co-expressed (Engler et al., 2008).  
The Golden Gate cloning method was utilised to create a 50 kb construct that contained 17 
transcriptional units (Werner et al., 2012). The construct was generated from assembling 68 
DNA fragments using three rounds of one-pot Golden Gate cloning. In a study by Celińska 
and colleagues (Celińska et al., 2017), the Golden Gate system was employed to construct a 
complex vector for expression of the carotenoid synthesis pathway. This consisted of 12 basic 
DNA fragments (promoter, gene of interest and terminator). The final expression vector was 
generated from the assembly of three transcription units and was then used to transform into 
competent Yarrowia lipolytica cells to investigate for the carotenoid production, showing that 
terpene pathways are amenable to this expression system. 
For this study, the Golden Gate cloning technology looked most suitable and so was chosen 
as a strategy to build a final expression vector containing the seven genes involved in the 
pleuromutilin biosynthesis pathway. 
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4.3.2 The principles behind Golden Gate assembly  
Golden Gate assembly is based on the use of type IIS restriction enzymes (Engler et al., 
2014). This group of enzymes recognize non-palindromic target sequences and cleave outside 
of their recognition site (Figure 28a) resulting in DNA overhangs that consist of specific 
unique sequences, allowing controlled, ordered assembly. By this process, DNA fragments 
flanked by compatible sequence overhangs could theoretically be ligated seamlessly. 
Furthermore, since the overhangs can be designed individually, the directional assembly of 
multiple fragments is feasible. This technology is claimed to be a powerful tool that allows 
highly efficient directional assembly of multiple DNA parts in a one-pot, one-step reaction 















Figure 28 Outline of the generic Golden Gate assembly process. (a) The type IIS restriction 
enzyme BsaI (or Eco31I) cleaves outside its recognition site and leaves unique 4-base 
overhangs. (b) Standard parts are cloned into plasmid backbones flanked by a pair of type IIS 
restriction enzyme recognition sites, and then all standard parts can be assembled into an 
acceptor plasmid flanked by compatible type IIS restriction enzyme recognition sites via a 
single digestion-ligation reaction. Image from Patron et al., (2015). 
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The Golden Gate process is split into several discrete steps. First each individual element is 
constructed, modified where necessary to ensure that they do not contain internal recognition 
sites for the various type II enzymes used in the process. These are termed level -1 fragments. 
These are then modified so as to have the appropriate restriction sites at each end, (level 0 
plasmids). These elements are joined together to form each separate expression cassette (level 
1 constructs) and these transcription units are then assembled, along with appropriate 
selectable markers or visual reporters either in one go, or stepwise, to deliver the final multi-
gene plasmid (level 2 plasmids). The different levels of plasmid each use different antibiotic 
resistance markers to allow easy selection of desired recombinants, (Figure 29). In this way, 
at least in theory, it should be possible to put at least 6 transcription units into one plasmid in 
one single step (Weber et al., 2011).  
 
 




































Figure 29 Illustration of the various levels within the Golden Gate Assembly Standard Protocol. Image from Engler et al., (2014).
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4.3.3 Module generation: the level -1 for removing internal type IIS enzyme target sites 
Basidiomycete genes typically contain numerous introns, so the plan was to express cDNA, 
as fungal introns likely would not splice correctly in plants. Close inspection of the various 
pleuromutilin gene cDNA sequences showed that six out of seven cDNAs contain several 
internal sites for Eco31I or BpiI, which would interfere with later steps in the vector 
construction and needed to be removed (Table 8).  
Table 8 The number of internal type IIS recognition sequences for each cDNA. 
 
GENE NUMBER OF TYPE IIS RECOGNITION 










The strategy to remove these sites is shown in Figure 30. Primers were designed overlapping 
the internal Eco31I or BpiI sites but containing a single nucleotide mismatch to eliminate the 
internal recognition sequence of Eco31I or BpiI. All PCR fragments could then be joined 
together using yeast homologous recombination along with the pYES2 backbone plasmid 
which had been previously digested with the restriction enzyme EcoRI. Fragments to be 
inserted into each backbone plasmid were amplified through PCR with Phusion High-fidelity 
DNA polymerase with specific primers that introduce a single nucleotide mismatch where 
needed. The modifications were designed to be silent mutations so no changes would be 



















Figure 30 The generic strategy to remove internal type IIS recognition sequences from the 
cDNA. To remove the internal BpiI and Eco31I sites within a fragment of gene, the specific 
primers were designed for amplifying between each site. The primers were designed to 
introduce a single nucleotide mismatch, so that the BpiI and Eco31I internal sites would be 
eliminated and the fragments could be assembled via yeast homologous recombination. 
 
Correct construction of pYES2/modified(m) of each cDNA was confirmed with PCR 
amplification of the desired gene (representative examples are shown in Figure 31-32. In 
addition, correct construction was also confirmed with restriction digest with the BpiI and 
Eco31I enzymes showing removal of the unwanted sites and with sequencing to confirm 
cDNA were error-free. Eventually this was successfully performed for all of the cDNA, 



















Figure 31 A) The predicted map for pYES2/mGGS without internal Eco31I and BpiI 
recognition sequences. B) Restriction digest showing correct construction of plasmid 
pYES2/mGGS, with loss of the restriction sites from the GGS cDNA: lane 1 contains 5 μL of 
hyperladder I (Bioline), lane 2 contains 10 μL of digestion reaction with restriction enzyme 
BpiI of pYES2/mGGS (expected fragments 2.7 kb, 1.6 kb, 1.1 kb, 980 bp, 453 bp and 10 bp), 
lane 3 contains 10 μL of digestion reaction with restriction enzyme Eco31I of pYES2/mGGS 
(expected fragments 5.8 kb and 946 bp were indicated in red) and lane 4 contains 1 μL of 
























Figure 32 A) Predicted map of pYES2/mCyclase vector contains Cyclase gene without 
internal Eco31I and BpiI recognition sequences. B) Restriction digest showing correct 
construction of plasmid pYES2/mCyclase, with loss of the restriction sites from the Cyclase 
cDNA : lane 1 contains 5 μL of hyperladder I (Bioline), lane 2 contains 10 μL of digestion 
reaction with restriction enzyme BpiI of pYES2/mCyclase (expected fragments 2.9 kb, 2.7 
kb, 1.6 kb, 980 bp, 453 bp and 10 bp), lane 3 contains 10 μL of digestion reaction with 
restriction enzyme Eco31I of pYES2/mCyclase (expected fragments 7.7 kb and 946 bp were 
indicated in red) and lane 4 contains 1 μL of undigested plasmid DNA of pYES2/mCyclase. 
Unlike the other six genes, P450-2 contains the highest number of BpiI and Eco31I internal 
sites. Moreover, the internal sites were close to each other, In order to recreate the site-free 
cDNA by yeast recombination, the rich internal sites region was divided into several very 
small fragments before assembling. These small fragments made it more difficult to purify 
the PCR products and also more challenging to assembly multiple fragments in yeast. After a 
number of failures to assemble the site-free cDNA by yeast recombination, the cDNA for 

















Figure 33 Plasmid map of the synthetic pDOWN/P450-2. 
 
Having confirmed removal of the unwanted restriction sites from all the individual genes, the 
next step was construction of Golden Gate level 0 vectors. 
 
4.3.4 Module generation: the level 0  
For construction of the level 0 modules, the sequences of the seven pleuromutilin genes from 
pYES2-based level-1 vectors and nptII gene from pCAMBIA2300 were each PCR-amplified 
using Phusion High-fidelity DNA polymerase, adding the desired fusion sites (four unique 
nucleotides of choice which complementary to allow annealing to the end of next fragment or 
the vector) and BpiI recognition site as part of the primers used for amplification, digested 
with BpiI and each cloned into the L0 acceptor plasmid pAGM9121 (Figure 34) via a Golden 
Gate cloning reaction, leading to creation of a level 0 module of each gene: pL0-GGS, pL0-




















Figure 34 The level 0 destination vector, pAGM9121 (pL0), confers spectinomycin 
resistance (SpecR) and encodes a lacZα fragment for blue/white selection. Two different type 
IIS recognition sequences -Eco31I and BpiI are flanked on both sides of the lacZα fragment 
in inverse orientation relative to each other. The DNA fragment of interest can efficiently 
clone into the vector via BpiI. After removing the BpiI recognition sites and lacZα, this 
design also provides further possibility to release the cloned fragment via Eco31I. 
The successful correct construction of pL0- of each of the seven genes was confirmed with 
restriction digest with the appropriate enzyme and PCR amplification of the genes inserted. 


















Figure 35 A) Predicted map of the pL0-GGS. B) Restriction digest showing correct construction of 
plasmid pL0-GGS:  lane 1 contains 5 μL of hyperladder I (Bioline), lane 2 contains 1 μg of digestion 
reaction with restriction enzyme Eco31I of pL0-GGS (sites shown in green, expected fragments 2.1 












Figure 36 A) Plasmid map of the pL0-Cyclase. B) Restriction digest showing correct construction of 
plasmid pL0-Cyclase: lane 1 contains 5 μL of hyperladder I (Bioline), lane 2 contains 10 μL of 
digestion reaction with restriction enzyme Eco31I of pL0-Cyclase (expected fragments 2.9 kb and 2.1 




It was noted that the Golden Gate assembly was far less efficient than expected, and was 
rather variable (Table 9), but in each case a level-0 plasmid was eventually successfully 
constructed. 
 












4.3.5 Module generation: the level 1 to create a transcriptional unit 
Compatible sets of sequenced level 0 modules (35S promoter, gene of interest, and nos 
terminator fragments) were then assembled into a level 1 vector with a second Golden Gate 
reaction using the enzyme Eco31I as outlined in Figure 37, leading to creation of a level 1 
module which is referred to as a transcription unit (TU). Each TU contains the promoter, 
gene of interest and terminator. The level 1 destination vectors confer ampicillin resistance in 
order to allow the efficient counter selection against level 0 backbones. Similar to the level 0 
destination vectors, two different type IIS recognition sites are also positioned on each side of 
lacZα fragment. This was performed for each of the eight required genes, generating pL1-

































Figure 37 A scheme for the construction of pL1 plasmids. The compatible set of promoter, gene and terminator was assembled via Eco31I 
enzyme of the Golden Gate assembly reaction. As a result, transcription unit of gene is created and hanging with BpiI on both sides, which is 
ready for the final assembly in level 2.
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Correct construction of pL1- plasmid of each gene was confirmed with PCR amplification of 
the genes inserted. Restriction digests with BpiI were done in order to confirm the completed 
pL1 plasmids that were ready for the final assembly in level 2. Examples are shown for GGS 










Figure 38 A) Plasmid map of the expression vector pL1-GGS. B) Restriction digest showing correct 
construction of plasmid pL1-GGS: lane 1 contains 5 μL of hyperladder I (Bioline), lane 2 contains 10 
μL of digestion reaction with restriction enzyme BpiI of pL1-GGS (expected fragments 4.4 kb and 1.9 











Figure 39 A) Plasmid map of the expression vector pL1-Cyclase. B) Restriction digest showing 
correct construction of plasmid pL1-Cyclase: lane 1 contains 5 μL of hyperladder I (Bioline), lane 2 
contains 10 μL of digestion reaction with restriction enzyme BpiI of pL1-Cyclase (expected fragments 
4.4 kb and 3.7 kb) and lane 3 contains 1 μL of undigested plasmid DNA of pL1-Cyclase. 
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As with construction of the level 0 plasmids, the success rate was variable and low for this 
reaction, but candidate level 1 cassettes were eventually constructed for all eight genes (Table 
10). 
Table 10 The proportion of successfully completed pL1 plasmids. 
 



























4.3.6 Module generation: making level 2 plasmids 
Numerous attempts were made to directly construct the complete level 2 plasmid containing 
all the pleuromutilin pathway genes, along with nptII for transformant selection in planta, 
however despite repeated attempts, no correctly constructed plasmids were obtained. 
Therefore, it was decided to initially work with only the early-stage genes to make plasmid 
construction easier and to validate these before moving to full pathway expression. GGS and 
Cyclase are the key enzymes responsible for the synthesis of 3-deoxo-11-dehydroxy-mutilin, 
the first metabolite in the pleuromutilin biosynthesis pathway, so the initial step of this 
project was to construct an Agrobacterium plasmid containing GGS and Cyclase using the 
Golden Gate assembly system.  The GGS/Cyclase plasmid could then be assessed via a 
transient expression in tobacco leaves, to assess the production of the first metabolite in 
pleuromutilin pathway in planta, this validation would help support the plan to then express 
the entire pathway. 
A BpiI-based Golden Gate cloning reaction was set up, including all three level 1 modules 
(pL1- GGS, pL1-Cyclase and pL1-nptII), a matching end-linker (EL), and a level 2 
destination vector, creating the final expression vector pL2- GGS/Cyclase/nptII (Figure 40). 
All level 2 destination vectors confer resistance to kanamycin and encode a red colour 





























Figure 40 A method for the construction of the level 2 expression vector containing GGS and Cyclase. The compatible set of transcription units 
for each gene was assembled together by the Golden Gate assembly reaction via BpiI. 
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The level 2 Golden Gate reaction for construction of pL2- GGS/Cyclase/nptII plasmid 
contained: 100 ng pAGM4673 plasmid (pL2 acceptor vector), 200 ng pL1-GGS, 200 ng pL1-
Cyclase, 200 ng pL1-nptII, 200 ng pEL-3, 1 µL BpiI, 1 µl T4 DNA ligase enzyme, 2 µl T4 
DNA ligase buffer, 2 µl Buffer G and was adjusted with water to 20 µl. The mixture was 
transformed into competent E. coli cells and plated on LB plates containing kanamycin. All 
ten transformant colonies tested showed the successful assembly of GGS, Cyclase and nptII 
genes when assessed by PCR (Figure 41). One plasmid was further confirmed by restriction 












Figure 41 PCR amplification products of GGS, Cyclase and nptII genes from pL2- 
GGS/Cyclase/nptII expression vector. Ten colonies of E. coli transformants were screen for 
the genes inserted: A) GGS (expected fragments 1057 bp), B) Cyclase (expected fragments 
2884 bp) and C) nptII (expected fragments 802 bp). Lanes from left to right: 1 = 5 μL of 
hyperladder I (Bioline), 2-11 = ten colonies of E. coli transformants, 12 = the plasmids 
pYES2/mGGS, pYES2/mCyclase and pCAMBIA2300 were used as positive controls and 13 















Figure 42 A) Plasmid map of pL2- GGS/Cyclase/nptII  and B) Restriction digest showing the 
correct construction: lane 1 contains 5 μL of hyperladder I (Bioline), lane 2 contains 10 μL of 
digestion reaction with restriction enzyme BamHI of pL2- GGS/Cyclase/nptII (expected 
fragments 7.0 kb, 2.6 kb, 1.2 kb and 596 bp) and lane 3 contains 1 μL of undigested plasmid 


















4.3.6.1 Assessing transient expression of pL2- GGS/Cyclase/nptII in N. tabacum 
The GGS/Cyclase expression plasmid was transformed into electro-competent cells of A. 
tumefaciens strain LBA4404 with selection for kanamycin cassette. Liquid culture was 
prepared and induced with acetosyringone to infiltrate tobacco leaves to detect products by 
transient expression. Three leaves of each plant were infiltrated 4-5 times with 1 mL of 
culture and plants maintained in a growth cabinet for three days.  After three days, the 
infected leaves were harvested and extracted with 100 mL ethyl acetate.  
The GGS and Cyclase genes was expected to produce, 3-deoxo-11-dehydroxy-mutilin 
(metabolite 1), the first metabolite in pleuromutilin biosynthesis pathway and previous 
research by Alberti et al., (2017) showed that this metabolite would be able to detect by TLC.  
The crude extract (2 µL) of N. tabacum pL2- GGS/Cyclase/nptII was separated on TLC and 
compared with the extract from A. oryzae GC-pdc TS2-2 (used as positive control) and N. 
tabacum containing empty vector (used as negative control) (Figure 43). The results had 
expected a high mobility product as previously seen in the Chapter 3. Unfortunately, the 
infiltrated tobacco gave a very complex profile on the TLC which prevented detection of 3-










Figure 43 Thin layer chromatography analysis of the crude extract from N. tabacum pL2- 
GGS/Cyclase/nptII compared with A. oryzae GC-pdc TS2-2. Spot 1: crude extract of A. 
oryzae transformant strains TS 2-2 containing GGS and Cyclase, spot 2: crude extract of N. 
tabacum containing pL2 containing empty vector and spot 3: crude extract of N. tabacum 
harbouring expression vector pL2- GGS/Cyclase/nptII.  
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4.3.7 Module generation: the level 2 of the final expression vector for the GGS, Cyclase 
and P450-1 genes 
Given the unsuccessful detection of 3-deoxo-11-dehydroxy-mutilin from the transient in 
planta assay, construction of the full expression plasmid was restarted. The pL2- 
GGS/Cyclase/nptII/P450-1 was constructed to add the P450-1 gene, which expected to 
generate 3-deoxo mutilin (metabolite 2). This metabolite would be more polar compared to 
metabolite 1 and would be able to be analysed through HPLC.  
The Golden Gate assembly to make the level 2 plasmid pL2- GGS/Cyclase/nptII/P450-1 was 
undertaken through the reaction mixture containing: 100 ng pAGM4673, 200 ng pL1-GGS, 
200 ng pL1-Cyclase, 200 ng pL1-nptII, 200 ng pL1-P450-1, 200 ng pEL-4, 1 µL BpiI, 1 µl 
T4 DNA ligase enzyme, 2 µl T4 DNA ligase buffer, 2 µl Buffer G and adjusted with water to 
20 µl. Then the mixture was transformed into competent E. coli cells and plated on LB plates 
containing kanamycin. Successful construction of pL2-GGS/Cyclase/nptII/P450-1 was 
confirmed with PCR amplification of each of the genes inserted and restriction digest with 










Figure 44 A) A map of predicted pL2- GGS/Cyclase/nptII/P450-1. B) Restriction digest 
showing correct construction of plasmid pL2- GGS/Cyclase/nptII/P450-1: lane 1 contains 5 
μL of 2-log ladder, lane 2 contains 10 μL of digestion reaction with restriction enzyme 
BamHI of pL2- GGS/Cyclase/nptII (expected fragments 6.1 kb, 3.3 kb, 2.6 kb, 1.2 kb and 




4.3.7.1 Chemical analysis of transgenic N. tabacum with pL2- GGS/Cyclase/nptII/P450-1 
The successful pL2-GGS/Cyclase/nptII/P450-1 construct was used to transform electro-
competent cells of A. tumefaciens strain LBA4404. Liquid culture inducted with 
acetosyringone were used to infiltrate tobacco leaves to induce transient expression. Five 4-6-
week-old plants of N. tabacum were used for Agrobacterium infiltration. Three leaves of each 
plant were infiltrated 4-5 times with 1 mL of culture and plants maintained in a growth 
cabinet for three days.  After 3 days, the infected leaves were harvested and extracted with 
100 mL ethyl acetate. The crude extract of N. tabacum pL2- GGS/Cyclase/nptII/P450-1 was 
detected through preparative HPLC compared with N. tabacum containing pL2 empty vector 
(used as negative control). 
From the ELSD chromatogram, no peak was eluted having the same m/z with expected 
metabolite 2. The mass of expected metabolite 2 was calculated to be = 351 m/z following 
the calculation previously used by Alberti et al., (2017). The predicted m/z value of 
metabolite 2 was scanned through the MS spectrum using MassLynx software but the attempt 
















Figure 45 Attempted detection of metabolite 2 from infiltrated tobacco. A and B) LCMS (ES-) spectrum from infiltrated and non-infiltrated 
leaves. C and D) Extracted ion traces (ES- -351) spectrum from infiltrated and non-infiltrated plants. This shows no readily detectable metabolite 
with m/z 351. 
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4.3.8 Module generation: the level 2-1 expression vector for the GGS, Cyclase, P450-1, 
P450-2 and P450-3 genes (5 genes) 
Further attempts to create the seven genes of pleuromutilin biosynthesis pathway assembled 
into level 2 construct were designed. Due to a large size plasmid construction and as the 
maximum number of transcription unit was limited to six which could be cloned in one round 
into a level 2 acceptor vector, the final construction was divided into two rounds: L2-1 and 
L2-2.  
The Golden Gate assembly of level 2 for pL2-1: GGS/Cyclase/nptII/P450-1/P450-2/P450-3 
plasmid was undertaken through the reaction mixture containing: 100 ng pAGM4673 
plasmid, 200 ng pL1-GGS, 200 ng pL1-Cyclase, 200 ng pL1-nptII, 200 ng pL1-P450-1, 200 
ng pL1-P450-2, 200 ng pL1-P450-3, 200 ng pEL-6 (lacZ), 1 µL BpiI, 1 µl T4 DNA ligase 
enzyme, 2 µl T4 DNA ligase buffer, 2 µl Buffer G and adjusted with water to 20 µl. The 
reaction was run in a thermocycler using the program as described earlier in Chapter 2 
Materials and Methods section 2.2.14. Then the mixture was transformed into competent E. 
coli cells and plated on LB plates containing kanamycin. Five transformant colonies showed 
the successful assembly of pL2-1 when assessed by PCR amplification of the genes inserted 























Figure 46 A) Predicted map for pL2- GGS/Cyclase/nptII/P450s B) Restriction digest 
showing correct construction of plasmid pL2-1 GGS/Cyclase/nptII/P450s: lane 1 contains 5 
μL of 2-log ladder, lane 2 contains 10 μL of digestion reaction with restriction enzyme 
HindIII of pL2- GGS/Cyclase/nptII/P450s (expected fragments 8.7 kb, 6.5 kb, 1.6 kb, 1.2 kb 
and 1.0 kb) and lane 3 contains 1 μL of undigested plasmid DNA of pL2- 
GGS/Cyclase/nptII/P450s. 
 
The correctly assembled L2-1 was then used for the final round of L2-2 plasmid construction 











4.3.9 Module generation: making the level 2-2 final expression vector for the seven 
genes of the pleuromutilin biosynthetic pathway 
The final round assembly for level 2-2 contains all seven genes involved in pleuromutilin 
biosynthesis pathway. The successful construct of pL2-1 was used as the destination vector 
for the addition of the last two transcription units: pL1-ATF and pL1-SDR.  
The level 2 Golden Gate assembly for the pL2-2 seven genes plasmid was undertaken 
through the reaction mixture containing: 100 ng pL2-1 plasmid, 200 ng pL1-ATF, 200 ng 
pL1-SDR,  200 ng pEL-1, 1 µL BpiI, 1 µL Eco31I, 1 µl T4 DNA ligase enzyme, 2 µl T4 
DNA ligase buffer, 2 µl Buffer G and adjusted with water to 20 µl. The reaction was run in a 
thermocycler using the program as described previously (section 2.2.14). The mixture was 
transformed into competent E. coli cells and plated on LB plates supplemented with 
kanamycin and X-gal. Three plasmids were confirmed by PCR amplification for the presence 
of all genes and restriction digest with the appropriate enzyme (Figure 47 and 48). Positive 




































Figure 47 PCR analysis of the level 2-7 plasmid confirming amplification products for GGS, 
Cyclase, nptII, P450-1, P450-2, P450-3, ATF and SDR genes. 
Lane 1 contains 5 μL of 2-log ladder: lanes 2-4 the extracted plasmids pL2-7 were used as a 
template; A) PCR amplification of the GGS gene (expected fragments 1057 bp), B) PCR 
amplification of the Cyclase gene (expected fragments 2884 bp), C) PCR amplification of the 
nptII gene (expected fragments 798 bp), D) PCR amplification of the P450-1 gene (expected 
fragments 1576 bp),  E) PCR amplification of the P450-2 gene (expected fragments 1582 bp), 
F) PCR amplification of the P450-3 gene (expected fragments 1573 bp), G) PCR 
amplification of the ATF gene (expected fragments 1138 bp), H) PCR amplification of the 
SDR gene (expected fragments 766 bp), in lane 5 the plasmid pL0 of each gene was used as a 














Figure 48 A) Map of the 7-gene plasmid pL2-7; GGS/Cyclase/nptII/P450-1/P450-2/P450-
3/ATF/SDR. B) Restriction digest showing correct construction of plasmid pL2-7: lane 1 
contains 5 μL of 2-log ladder, lane 2 contains 10 μL of digestion reaction with restriction 
enzyme BamHI of pL2-7 (expected fragments 5.9x2 kb, 3.3 kb, 2.6x2 kb, 1.2 kb, and 596 bp) 














4.3.10 Agrobacterium infiltration of N. tabacum  
N. tabacum was chosen as a host to assess the transient expression of genes involved in 
pleuromutilin biosynthesis pathway. Four expression vectors; 1) pL2/GGS/CYC/nptII, 2) 
pL2/GGS/CYC/nptII/P450-1, 3) pL2/GGS/CYC/nptII/P450-1/P450-2/P450-3 and 4) pL2-7   
were used for Agrobacterium infiltration (Figure 49). Each plasmid was transformed into 
electro-competent cells of A. tumefaciens strain LBA4404 and was used to infiltrate tobacco 














Figure 49 The progressive development of symptoms in N. tabacum every 2 days after 
infiltrating with Agrobacterium containing pL2 expression vector harbouring various genes 
involved in the pleuromutilin biosynthesis pathway; A) Control = empty pL2 vector, B) 2 
genes = GGS and Cyclase, C) 3 genes = GGS, Cyclase and P450-1, D) 5 genes = GGS, 
Cyclase, P450-1, P450-2 and P450-3 and E) seven genes of pleuromutilin cluster. 
116 
 
After 13 days of observation, the leaves which were infiltrated with each plasmid presented 
the yellowish lesions from the infiltration spots, while no lesion was found on the empty 
vector. Among them the leaf infiltrated with the 7 genes plasmid showed more extensive 
chlorosis when compared with other infiltrated leaves (Figure 49E). In addition, the 
development of chlorosis seemed to increase correlated with the number of genes in the 
expression vector. Alberti et al., (2017) showed increasing antibacterial properties for mutilin 
compounds as they progress towards being the final mature product and the observed 
increase in chlorosis seems to correlate with this. 
Results suggest constructs are active, but the resulting product is below the threshold for 
detection with this method or is not extractable from the leaf. The chlorosis suggests in planta 
production is toxic so a stable transgenic route is not appropriate with these vectors, as 






















4.4 Discussion  
Plant-based systems are now gaining acceptance as reliable expression platforms for 
heterologous expression, especially for the production of recombinant proteins in the 
pharmaceutical industry. Among various plant species, tobacco is one of the most suitable 
hosts to be used as a heterologous system for the production of secondary metabolites. This 
plant-based system provides numerous advantages over the other plants; as a leafy plant it is 
capable of the production of high biomass, it has well-established methods for transformation 
procedures, it is classified as a non-food, non-feed crop so it reduces risk of contamination in 
the feed or food chain (Abiri et al., 2015, Fischer et al., 2004). To date, various types of 
vaccines and antibody have been produced in tobacco. A full length of a mouse catalytic 
IgG1(6D4) monoclonal antibody was the first antibody generated in tobacco (Hiatt and 
Pauly, 2006), as well as other antibodies that targeted different diseases such as anthrax, 
hepatitis, rabies etc.  (Girard et al., 2006, Gleba et al., 2005, Hull et al., 2005). So, tobacco 
was chosen as a new platform for heterologous expression of pleuromutilin biosynthesis 
pathway within this project. 
The selection of an appropriate plant expression vector was another crucial factor for this 
project. The goal is to recreate the whole pleuromutilin biosynthesis pathway then transfer for 
heterologous expression in planta. However, the pathway consists of seven genes all of 
which need refactoring for expression. In the fungal host A. oryzae, the seven genes were 
divided into three plasmids and several rounds of transformations were performed. A similar 
procedure could be employed in tobacco, but it was considered as a time-consuming process. 
In order to simplify the multi genes assembly, the Golden Gate assembly method was chosen 
as a strategy to assemble the seven genes of pleuromutilin pathway into plant expression 
vector for this project. The method based on the ability of type IIS enzymes was proven to be 
efficient and reliable for the multiple fragments assembly (Engler et al., 2008, Engler et al., 
2014, Lampropoulos et al., 2013, Weber et al., 2011) and the availability of well-validated 
promoter and terminator regions in the toolkit. 
At the beginning numerous attempts were performed to assembly the seven genes involved in 
the pleuromutilin production, but after countless repeated trials no correct construct could be 
obtained suggesting the process was not as simple as the literature had claimed. Therefore, 
the construction of the expression vector containing just the GGS and Cyclase genes involved 
in pleuromutilin biosynthesis pathway was done by using the Golden Gate cloning reaction. 
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The effort was to focus on the bottleneck step to enhance the production of the most upstream 
precursor to go through the other steps along the pathway and result in the increase of 
pleuromutilin titre at the end. Results from TLC analysis of infiltrated N. tabacum pL2- 
GGS/Cyclase/nptII did not show a spot of the expected metabolite 1, but the likely reason 
might due to numerous compounds produced in planta which could be interfered spot of the 
expected metabolite, the production was not confirmed. 
Next step approach was to add P450-1 gene into the expression vector with the aim of 
generating the metabolite 2 which has a higher polarity and would be able to be investigated 
it through preparative HPLC. Unexpectedly, chemical analysis failed to detect any trace of 
metabolite 2 by HPLC. There are several possible reasons to account for the lack of 
accumulation of the expected metabolite in tobacco. The small batch of plant samples with 
just five plants might lead to a low yield of metabolite 2 in the crude extract or the fungal 
P450 may not function in a plant cell. 
Another issue that has to be considered is the production of unexpected compound resulting 
from the modification by endogenous enzymes of the host system. Various reaction such as 
oxidation, glycosylation and dephosphorylation within the host system might give chance to 
produce a new compound, but it is also the possibility of having produced a toxic compound 
and since plants evolved many defensive mechanisms against pathogens and environmental 
stress (Reed and Osbourn, 2018, Zhang et al., 2011),  any possible metabolite produced by 
these three genes might be detected and broken down by the host before it can be 
accumulated.  
Many attempts failed to construct the seven genes plasmid at the beginning of the project as 
the construction did not work according to the theoretically principle. With Golden Gate 
working more reliable it was feasible to make a wide range of vectors, but this highlights the 
need for experience work for the system to be able to use it efficiently. The key point to be 
noted is the number of cycles for the restriction-ligation reaction. The results from this 
project correlated to the results from prior studies (Engler et al., 2008). that when comparing 
the short reaction of 30 cycles and the long reaction of 50 cycles, the long cycle showed a 
significant increase in the number of the desired colonies. In addition, many false positive 
colonies were found within this project. The sequence analysis of those constructs was not 
done in this project. In the other studies, it was suspected that the possible reason for this 
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might be the formation of dimer structures of the vectors and inserts (vector-insert-vector-
insert) of the recombinant plasmids but this was not performed in this study. 
Despite many difficulties, the final attempt was successful to construct the expression 
plasmid containing all seven genes of pleuromutilin biosynthesis pathway. The investigation 
of transient gene expression of the seven genes in tobacco was carried out, the result showed 
a yellowish lesion on transgenic plants but none on the empty vector construct. Even though 
it was not clear that pleuromutilin metabolites were produces in planta, it could be assumed 
that there was some production of an unknown metabolite in the plants that was associated 
with these genes products, however, the production of the unknown substance seemed to be 
toxic to the plants. Many possibilities could exist for the occurrence of the yellowish lesion as 
follows. 
Firstly, if the initial hypothesis was right, the seven genes in pleuromutilin cluster was 
expressed and resulted in the production of pleuromutilin in planta. These pleuromutilin 
metabolites may affect the growth or survival of the plant. Pleuromutilin antibacterial activity 
is by binding to the ribosome of bacteria and inhibiting its protein synthesis. The biological 
evolution points out that the organelles such as mitochondria or chloroplast in eukaryote were 
of bacterial origin. According to the endosymbiosis theory, the organelles in eukaryote cells 
could be originated from endophytic prokaryote organisms when the eukaryote cell engulfed 
the prokaryote through symbiosis. Therefore, the organelle ribosomes in plants could be 
similar to the ones in the bacteria and hence sensitive to pleuromutilin (Gruber, 2019, 
Zimorski et al., 2014). This is probably the best explanation why the plant is affected by 
pleuromutilin. It was not investigated whether pleuromutilin is toxic to the chloroplast or 
mitochondrial ribosome, but the extensive chlorosis might indicate a chloroplast-based effect. 
In nature, plants produce and store diterpene compounds in leucoplasts (Zi et al., 2014). 
Leucoplasts differ from chloroplasts because they lack photosynthetic pigments. The 
biosynthetic genes for the production of monoterpene limonene have been found to be highly 
expressed in glandular trichomes (Jongedijk et al., 2016). A similar result was also found in 
the study of the biosynthesis of the well-known sesquiterpene compound, artemisinin, 
showing that it is produced in the cells of trichromes (Zhang et al., 2011). Therefore, it should 
be considered that the specific cell type in plants may provide the cellular compartment and 
biochemical environment that is suitable for the production of terpene compounds and it is 
unclear whether the transient Agrobacterium infiltration would deliver the gene to these cells.  
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In addition, the 35S promoter of the cauliflower mosaic virus was used for the constitutive 
expression of the genes in this study. It would be interesting to investigate the use of tissue 
specific promoters or inducible promoters to drive the genes. The inducible promoters may 
provide a possibility to induce or upregulate the genes at a specific stage of plant 
development or specific tissue of interest, then allow the metabolites to accumulate (Borghi, 
2010). A previous study reported success using an ethanol-inducible promoter to enhance the 
levels of recombinant protein expression upon induction, up to 4.3 mg/g fresh biomass in 
transgenic Nicotiana benthamiana plants (Werner et al., 2011). Such an approach may work 
for increasing metabolite levels. 
A different possibility is that the heterologous expression of P450 genes did not function 
correctly in the plant host system. The activity of P450s are dependent on the supply of 
NAD(P)H and electrons. Cytochrome P450 reductase, as a redox partner of the P450 
monooxygenase, also plays a crucial role to achieve optimal P450s activity (Durairaj et al., 
2016). The work from Zhang et al., (2011) showed the possibility of the accumulation of 
artemisinin precursors through the heterologous expression of A. annua cytochrome P450 
(CYP71AV1) and artemisinic aldehyde Δ11(13) double-bond reductase (DBR2) in transgenic 
tobacco. Even though, the result of their study might give hope for the heterologous 
expression of P450 gene in plant system, but this was a heterologous expression of plant 
P450 in another plant. The expression of fungal P450s in planta has not been reported in any 
previous study yet, so in this study plant Cytochrome P450 reductase might not reactivate 
fungal P450s. To my knowledge, this project might be the first attempt for the heterologous 
expression of fungal genes in planta. 
As the expression analysis of the genes was not carried out within the project, it is unknown 
whether the genes were expressed or not, but the promoters are all well-validated and so 
likely to be functional. Further investigation is needed to be carry out for the understanding of 
the mechanisms of the enzymes and to ensure that the full potential of enzyme activities 







The work in this chapter provided the information for the alternative platform for the 
heterologous expression of genes encoding the pleuromutilin biosynthesis pathway in 
infiltrated tobacco. The results failed to detect the desired intermediate through HPLC 
analysis. This could indicate many possibilities; the yield was too low, the cellular 
environment in planta was not suitable for the metabolite production or it was broken down 
by the host defensive mechanisms before it could be accumulated within the plant. 
Nevertheless, the expression of fungal genes in plant remain unexplored and unexploited. The 
further challenge and a better understanding of the fungal genes in plant could open the 
possibilities to generate a reliable platform for fungal metabolite production for various 




















Chapter 5 Heterologous expression of pleuromutilin biosynthetic 
genes in yeast system  
5.1 Introduction 
The heterologous expression of the pleuromutilin biosynthetic pathway in the fungal host 
system, A. oryzae and plant-based system, N. tabacum did not give the expected result in the 
improvement of pleuromutilin production. Therefore, the yeast Saccharomyces cerevisiae, 
another promising heterologous host system, was chosen as an alternative host for the 
expression of this antibiotic gene cluster.  
Terpenoids are the largest class of natural products, which include more than 50,000 
compounds that have significant commercial applications ranging from food flavours, 
fragrances, cosmetics to medicines (Ignea et al., 2011). Isopentenyl diphosphate (IPP) and its 
isomer dimethylallyl diphosphate (DMAPP) are the two general precursors for the 
biosynthesis of all terpenoid compounds. The IPP and DMAPP units are derived through 
either the mevalonate pathway (MVA) or the methylerythritol phosphate pathway (MEP) 
(Zhang et al., 2017). In yeast IPP is synthesized through the MVA pathway. The 
condensation of IPP and DMAPP, catalytic reaction through ERG20 gives rise to higher 
building blocks of geranyl pyrophosphate (GPP; C10), farnesyl pyrophosphate (FPP; C15) and 
geranylgeranyl pyrophosphate (GGPP; C20), which are the substrates of mono-, sesqui- and 
di- terpene synthases, respectively. The action of those terpene synthases together with their 
substrate will generate the terpene hydrocarbon scaffold of monoterpenes, sesquiterpenes and 
diterpenes (Figure 50). Yeast does not normally produce many terpenoids as most of the 
product from the MVA pathway are used for sterol biosynthesis. However, previous studies 
in yeast showed the successful expression of a plant terpene synthase derived from T. 
chinensis for the production of taxol, a diterpene compound used as an anticancer agent and 
another plant terpene synthase derived from A. annua for the production of artemisinin, a 
sesquiterpene compound used against malaria. This demonstrated that it was possible for the 
exogenous terpene synthase enzymes to use the endogenous substrates for the production of 












Figure 50 Illustrated the mevalonate pathway for terpenoids biosynthesis in yeast. Modified 
from Kampranis and Makris, (2012). 
 
5.1.1 Successful metabolic engineering cases for the production of terpenoids in yeast 
5.1.1.1 Taxol 
The recent metabolic engineering study by Engels et al., (2008) demonstrated a successful 
production of taxadiene, a precursor of taxol in yeast Saccharomyces cerevisiae. Taxol is a 
diterpene compound, originally extracted from the bark of the pacific yew tree (Taxus 
brevifolia). Taxol and its derivatives are known as effective chemotherapy agents use for the 
treatment of cancer. The obstacle that prevents its large-scale production is the low yield of 
the extract from its natural plant source. Despite a successful total chemical synthesis (Holton 
et al., 1994, Nicolaou et al., 1994), its complex structure leads to a laborious and costly 
processes. The taxol biosynthetic pathway (Figure 51) consists of at least 19 enzyme-
catalysed steps starting from the diterpene precursor GGPP, followed by the catalytic reaction 
via taxadiene synthase to generate the taxa-4(5), 11(12)-diene or also known as taxadiene. 
Taxadiene then will be oxygenated through several cytochrome P450 monooxygenases to 
yield taxol (Engels et al., 2008). The metabolic engineering approach to create the taxol 
biosynthetic pathway in yeast provides the possibility to establish the specific steps within the 















Figure 51 The taxol biosynthetic pathway from Engels et al., (2008). 
 
Engels et al., (2008) reported several approaches to engineer the early part of the taxol 
biosynthetic pathway for the improvement of yield of the taxadiene compound in the yeast S. 
cerevisiae. Firstly, they introduced the heterologous expression of taxadiene synthase derived 
from Taxus chinensis, but the results showed no accumulation of taxadiene and the possible 
reason they proposed was an insufficient supply of the precursor GGPP. The next step was 
the co-expression of taxadiene synthase and GGPP synthase indicate on pathway from T. 
chinensis; the result also failed to show any improvement of taxadiene level. In yeast, most of 
the output from the MVA pathway is used for the biosynthesis of ergosterol, which is a major 
component of the cell membrane. The previous study from Ro et al., (2006) showed that by 
using a shortened version of yeast HMG-CoA reductase, steroid-based negative feedback was 
prevented and there was increased supply of precursor for other terpene compounds. Using 
the truncated HMGR, Engels et al., (2008) showed the increase of taxadiene to 306±3 µg/L. 
Another attempt to inhibit sterol production is based on the mutagenesis of UPC2, a key 
regulatory factor to allow steroid uptake in yeast under aerobic growth condition. The 
expression of the mutant UPC2 gene along with the previous three genes, resulted in a 50% 
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increase of yield of taxadiene. For the last attempt, they replaced the GGPP synthase from T. 
chinensis with the GGPP synthase from a thermophilic archaeon Sulfolobus acidocaldarius, 
in order to increase the GGPP precursor through the DMAPP building block and avoid the 
competition of steroid synthesis via FPP. The result showed a significant increase of a 40-
fold in taxadiene production. 
 
 
5.1.1.2 Artemisinin  
Artemisinin is a sesquiterpene compound with a potent antimalaria property. Its original 
source is the herb, Artemisia annua. Studies showed that artemisinin and its derivatives also 
have additional pharmacological properties including antiparasite, anticancer, and antiviral 
activities (Efferth et al., 2008, Keiser and Utzinger, 2007, Wong et al., 2017). A problem with 
this drug is that the demand and supply are not balanced meaning lots of patients cannot 
access the drug because of high price (Chandran et al., 2011). Like taxol, the production from 
its natural source is very limited. The approach for chemical synthesis of the compound is 
complicated and not cost-effective. The alternative strategies to solve the problem might be 
by improved agricultural procedures, microbial production, and the development of synthetic 
processes (White, 2008). 
The study from Ro et al., (2006) (Figure 52) reported that engineered S. cerevisiae strains 
could produce a high titre of artemisinic acid. Their first approach started from engineered 
strains that increase FPP production and decrease it use for sterol synthesis. Use of strain 
EYP208 overexpressing a short version of 3-hydroxy-3-methyl-glutaryl-coenzyme A 
reductase (tHMGR), resulted in five-fold increase of amorphadiene production. The strain 
EYP225 created by downregulation of ERG9, the gene responsible for the conversion of FPP 
into the sterol biosynthetic pathway, resulted in a further increase in titres of amorphadiene 
production by two-fold. Following that the EPY213 strain was generated with the 
combination of downregulation of ERG9 and overexpression of UPC2-1, yielded the 
amorphadiene production up to 105 mg/L. Next tHMGR was introduced into the EPY213 
strain and generated EPY219, that showed the further increasing of amorphadiene production 
up to 149 mg/L. Lastly, the final strain EPY224 was engineered by combining all those 
modifications and including the overexpression of ERG20, as a result the production of 
amorphadiene was up to 153 mg/L. Finally, the EPY224 then was used for the transformation 
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with vector containing cytochrome P450 monooxygenase together with its redox partner from 
A. annua (CYP71AV1/CPR), the extract from shake-flask culture provided 32±13 mg/L of 
















Figure 52 Diagram of the artemisinin production pathway from Ro et al., (2006). 
 
The engineered yeast S. cerevisiae strains for the production of taxol and artemisinin clearly 
provided a possible platform for a higher yield production of the early stage of pleuromutilin 





The aim of the work reported in this chapter was to create the yeast expression vector for the 
early steps of pleuromutilin biosynthesis pathway and to compare the production efficiency 
of two different heterologous yeast strains. 
 
Several objectives were set in order to complete the aim:  
1. To construct the yeast expression vectors for GGS and Cyclase genes  
2. Yeast transformation for the heterologous expression under the control of inducible    
    promoters 
3. Chemical analysis to evaluate and compare the yield of the first metabolite extracted from  
















5.3.1 Design and construction of the expression vector pESC-TRP/GC 
 
The YPH499 strain of S. cerevisiae is a typical lab yeast strain, which contains non-revertible 
auxotrophic mutations that can be used for the selection of inserted vectors. The YPH499 
strain was used for the heterologous expression of GGS and Cyclase genes from 
pleuromutilin biosynthesis pathway to accumulate the 3-deoxo-11-dehydroxy-mutillin 
(metabolite 1), the main precursor of the pathway. 
The pESC-TRP vector was used as a backbone vector to construct the expression vector for 
GGS and Cyclase genes. The pTYGSargGGSCYC plasmid was utilized as a template vector 
to amplify the GGS and Cyclase genes. The PCR product of GGS was cloned into the NotI 
restricted site of vector pESC-TRP under the control of the GAL10 promoter, while, the PCR 
product of Cyclase was cloned into the BamHI restricted site of vector pESC-TRP under the 
control of the GAL1 promoter. The correct construction of the plasmid was checked by PCR 












Figure 53 Gel electrophoresis showed the successful PCR amplification of A) GGS and B) 










Figure 54 A) The plasmid map of pESC-TRP/GC B) gel electrophoresis of restriction 
digestion reaction of the pESC-TRP/GC vector with XhoI enzyme. Lane 1 contains 5 μL of 2-
log ladder. Lane 2 contains 10 μL of digestion reaction with restriction enzyme XhoI of 
expression vector pESC-TRP/GC (expected fragments 8.9 and 1.3 kb). Lane 3 contains 1 μL 
of undigested plasmid DNA of pESC-TRP/GC. 
 
Having confirmed that the plasmid was properly constructed, pESC-TRP/GC vector was 
introduced into the yeast YPH499 strain through the yeast transformation procedure 
following the method described in Chapter 2. The selection of yeast transformant strains was 











5.3.1.1 Chemical analysis of 3-deoxo-11-dehydroxy-mutilin in the yeast YPH499 strain 
In order to assess the 3-deoxo-11-dehydroxy-mutilin (metabolite 1) accumulation, three 
independent colonies containing pESC-TRP/GC, named YGC 1, 2 and 3 were subsequently 
picked and used to inoculate in 5 mL yeast minimal media lacking tryptophan as a starter 
culture and incubated overnight at 28oC in incubator shaker. On the following day, the starter 
culture was determined the absorbance at 600 nm, to reach OD600 = 1.0. The 1 mL aliquot of 
these cultures were transferred into the flask contained 50 mL of sterile yeast minimal 
medium lacking tryptophan and supplemented with galactose, as the genes under the control 
of GAL promoters require galactose for induction. The control flask also contained the same 
medium but no supplement of galactose. The cultures were analysed for the metabolite 1 
production after 6 days of incubation at 28oC.  
To evaluate the metabolite 1 production, the cultures were extracted following the procedures 
in Chapter 2 and analysed on the TLC plate. The results showed that all extracts from yeast 
transformants YGC 1, 2 and 3 produced the expected metabolite 1 (Figure 55). Especially 
extract from strains YGC 2 and 3 that showed more accumulation of expected product than 
the negative control strain (N) containing the empty vector pESC-TRP. Even though the 
hypothesis was expected no production of any metabolite in negative control strain, but the 
spots revealed from negative control strain suspected to happen through the contamination 
during extraction processes. While no accumulation found on the extract from A. oryzae 
strain TR5 containing GGS and Cyclase used as a positive control which might due to the 


















Figure 55 TLC analysis of chemical extracts from yeast strains YGC 1, 2 and 3 harbouring 
pESC-TRP/GC, grown in two different liquid culture conditions: with and without galactose 
supplement, compared with N; the YPH499 strain containing empty vector pESC-TRP (as 
negative control), and P; the crude extract from A. oryzae strain TR5 containing GGS and 
Cyclase genes (as positive control). 
 
5.3.2 Strain construction and chemical analysis of 3-deoxo-11-dehydroxy-mutillin in the 
engineered AM109 strain 
The AM109 strain of S. cerevisiae was engineered by focusing on the 3-hydroxy-3-methyl-
glutaryl-coenzyme A reductase (HMGCR), the rate-limiting step enzymes responsible for 
converting HMG-CoA to mevalonate in MVA pathway. These enzymes are usually sensitive 
to degradation. Thus, by containing three copies of stable versions of HMGCR, plus the 
deletions of three genes encode for enzymes that have a degradation effect on HMGCR, 
resulting to the AM109 strain that was proven to help increase the flux towards terpene 
precursor (Ignea et al., 2012). 
In this project, the hypothesis was that by using the AM109 strain as a host for the expression 
vector for pESC-TRP/GC, it should gave rise to higher level of metabolite 1 production than 
the normal YPH499 strain. Yeast transformation and selection of transformant strains was 
done with the same procedures as in the previous YPH499 strain. The chemical analysis to 
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determine the production of metabolite 1 was carried out under the same protocol as 
described earlier. The hexane extract from AM109 transformant strains AGC 1 and 2 
containing pESC-TRP/GC vector were visualized through TLC analysis. Unfortunately, the 
results from TLC plate (Figure 56) showed the similar pattern as appeared in the YPH499 
transformant strains. For a better understanding, an attempt to purify and identify the 









Figure 56 TLC analysis of the crude extracts from yeast strain AGC 1 and 2 containing 
pESC-TRP/GC, grown in two different liquid culture conditions: with and without galactose 
supplement, compared with negative control (N); the AM109 strain containing empty vector 
pESC-TRP and positive control (P); the extract from A. oryzae strain TR5 containing GGS 








5.4 Discussion  
According to the heterologous expression of pleuromutilin biosynthetic pathway in A. oryzae 
and N. tabacum host systems, the results from both systems failed to show an increasing of 
pleuromutilin production. Then, in this chapter yeast-based system platform was chosen as a 
host for the heterologous expression of the GGS and Cyclase genes. It is anticipated that by 
increasing the production of the first metabolite from the expression of GGS and Cyclase will 
lead to increase the flux supply of the bottleneck precursor through the whole pleuromutilin 
pathway.  
Firstly, the yeast strain YPH499 was used for the heterologous expression of pESC-TRP/GC 
vector. From the TLC analysis, the extract from all YPH499 transformant strains showed 
accumulation of expected metabolite 1. This suggest a possibility of yeast as a host for the 
heterologous of the pleuromutilin biosynthesis pathway. However, it worth to note that the 
negative control strain supposed to not produce any metabolites, but the spots found from this 
strain might be occurred through the contamination whether during fermentation or extraction 
processes. Further attempt was done by using engineered S. cerevisiae strain AM109, which 
harboured a set of modified genes that has been proven to increase the production of terpene 
compounds, as a host for the heterologous expression of pESC-TRP/GC vector by aiming 
that the production of metabolite 1 should be higher than the YPH499 strains. Unfortunately, 
the results from TLC analysis from the extracts of AM109 transformant strains 1 and 2 
seemed to give low accumulation of metabolite 1 than in the YPH499 strains. However, the 
spots that obviously found from both YHP499 and AM109 transformant strains could 
possibly suggested a potential of yeast host to generate a new metabolite. 
It is possible that the spots from TLC analysis of the non-induced galactose group could have 
happened due to too long period of time used to culture yeast cells. This factor could lead to a 
starving condition for yeast cells. Generally, glucose as a carbon source in the media causes 
repression of the GAL promoters, so the depletion of glucose during starving condition could 
possibly have implications to the leaky effect of the GAL promoters. This suggested that by 
shorten the culture period to 48-72 hours might be able to prevent this problem. A similar 
condition was reported in a study in which focusing on the effect of glucose concentration on 
the GAL promoter (Peng et al., 2018). The 48-hour colonies were cultured and collected for 
fluorescence analysis of yEGFP gene under control of the GAL promoter. As a result, the 
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colonies from the 200 g/L glucose showed higher expression of yEGEP than the colonies 
from the 20g/L glucose in liquid cultures (Peng et al., 2018). 
Previous study from Engels et al., (2008) showed no accumulation of the early part of the 
taxol biosynthetic pathway using plant GGS and Cyclase genes. But in this study, the results 
demonstrated the possibility for the early stage of the pleuromutilin pathway production, 
using fungal GGS and Cyclase genes. Thus, it can be concluded that heterologous expression 
of fungal genes is more efficient than the plant genes in yeast. This suggests the potential of 
yeast as a host for further modification of the pleuromutilin biosynthetic pathway in this host 
system. 
Lastly, to construct a complete pleuromutilin biosynthesis pathway in yeast, the host has to 
go through several rounds of transformation. The genes in pleuromutilin cluster needed to 
split into several vectors due to the limitation of promoters and selective markers in yeast. 
Then, at least 10 transformants strains harbouring the desired genes are needed to be screened 
for a more reliable result. Additionally, analysis for the expression of genes need to be done 
in order to select a transformant with highly expressed of the genes which have a capacity to 
accumulate an intermediate before entering another step of the pathway. 
 
5.5 Summary 
Heterologous expression of pleuromutilin biosynthetic pathway in yeast has shown to be a 
potential platform for enhancing the production of the antibiotic drug. In addition, this system 
also suggested a possibility to generate a new metabolite. However, the carefulness during 
the fermentation and purification processes have to be noted to prevent a contamination. The 
attempt to analyse and identify the new metabolite for its antibiotic property have to be 
further investigated. Moreover, in order to increase pleuromutilin production, the other 
following genes within the pleuromutilin gene cluster needed to introduce into the yeast cells, 








Chapter 6 Discussion 
 
The antibiotic resistance crisis is recognized as a major threat for human health to controlling 
infectious diseases worldwide. The problem leads to three major effects; higher medicinal 
cost, prolonged hospital stays and increased mortality. Each year around two million people 
in the United States are affected by bacteria resistant to antibiotics, with approximately 
23,000 individuals dying from these infections (Martens and Demain, 2017), while 25,000 
people in Europe are killed by drug-resistant bacteria per year. According to the World 
Health Organization (WHO), the worldwide healthcare could lose as much as $100 trillion or 
£65 trillion annually for the treatment of antibiotic resistance (Arias and Murray, 2015). 
Despite an urgent and serious concern to find new effective drugs to treat infections, only a 
few new drugs have been developed and introduced into the market since the golden era of 
antibiotic (Ventola, 2015). To overcome the problem of high bacterial resistance, and no new 
drugs to treat the infection, renewed research efforts are currently focusing on finding and 
developing new classes of antibiotic. 
 
Pleuromutilin, a natural-product antibiotic from the fungus Clitopilus passeckerianus, has 
gained a lot of scientific attention for its unique mechanism of action. It showed a strong 
activity toward multidrug-resistant MRSA strains by inhibiting protein synthesis in bacteria. 
The drug also has no target-specific cross-resistance to other antibacterials (Paukner and 
Riedl, 2017). Recent study from Llabani et al., (2019), also reported that chemical 
modification of pleuromutilin structure leaded to a set of compounds in which biological 
screening provided a potential to induce the death of cancer cells. These attractive profiles of 
pleuromutilin make it more appealing for the development of the drug for potential human 
use. In August 2019, lefamulin (XenletaTM), a semisynthetic pleuromutilin was successfully 
developed and approved by FDA to treat Community-acquired bacterial pneumonia in adult. 
It was the first systemic antibiotic available for both oral and injection forms that has 
launched into the market over the past twenty years (FDA, 2019). But the commercial cost of 
the drug is too high, therefore limiting access for number of patients. 
 
Thus, further approaches in the development of pleuromutilin production that would be able 
to meet the growing demand in the future along with the affordable price are still needed. 
Heterologous expression systems for the production of pharmaceutical compounds is a 
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rational strategy to use as an attempt to overcome the difficulties of low production from the 
original host. It is also providing the opportunity to manipulate the function of genes involved 
in this biosynthetic pathway more readily or even to generate path for the production of new 
compounds. Earlier successful cases of drug use in human such as insulin, artemisinin and 
antibodies also utilised heterologous platforms. The production of insulin for treatment of 
human diabetic is now being produced mainly in E. coli and Saccharomyces cerevisiae 
(Baeshen et al., 2014). Zmapp, a monoclonal antibody that was developed to fight against the 
outbreak of Ebola virus infection, was also produced in tobacco plants (Yao et al., 2015). 
Many efforts of partial biosynthesis for the production of artemisinin and taxol, by providing 
the precursor of the biosynthetic pathway towards the heterologous systems, resulted in 
increasing titres of the desired metabolites (Fu et al., 2020, Chen et al., 2019). These 
examples suggest a potential for heterologous systems for improvement of pleuromutilin 
production. To this content, the aim of this PhD project was to find alternatives and more 
flexible heterologous systems in order to potentially enhance the yield of pleuromutilin 
production. 
 
In order to make attempts to enhance and develop the production of pleuromutilin, the basic 
knowledge of its biosynthetic pathway and the identification of genes involved in each step is 
required. Fortunately, the previous study has already reported and identified that there are 
seven genes consisting in the pleuromutilin biosynthetic gene cluster (Bailey et al., 2016). 
Characterization of the function of each gene, which led to the accumulation of the 
intermediates along the pathway by heterologous expression, was also done by Alberti et al., 
(2017). The next challenging step is to choose the most appropriate heterologous host system 
for the expression of the pleuromutilin gene cluster which could lead to higher production 
level, then case-by-case analysis of each system is required. Within this PhD project, three 
different heterologous host system; fungal (A. oryzae), plant (N. tabacum) and yeast (S. 
cerevisiae) were chosen for the expression of the pleuromutilin gene cluster.  
 
Results from this project suggested the advantages and disadvantages of each heterologous 
host systems for the attempts to enhance pleuromutilin production and can be concluded in 
several issues. Undoubtedly, there are some challenges in order to recreate the whole 
pleuromutilin biosynthesis pathway and perform functional expression of the seven genes 
involved in the heterologous hosts. The results from this study showed that the plant-based 
system provided the most appropriate cloning method to reconstruct the expression vector of 
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pleuromutilin biosynthesis pathway. The Golden Gate cloning kit for plants used in this 
project providing 96 standard parts that include plant promoters, reporter genes, antigenic 
tags, selectable markers, and terminators (Engler et al., 2014). This molecular toolkit allowed 
the seven genes in pleuromutilin biosynthesis pathway to be assembled into one expression 
vector, even though the efficiency of the cloning was lower from what it claimed from the 
journal. In this study, successful constructs containing the seven genes of pleuromutilin 
biosynthesis pathway, which was used to transform with just one round into the tobacco 
plant, showed the advantage in term of time scale of transformation process when compared 
to the fungal and yeast system. In case of the yeast host, the availability of the cloning sites 
became a limiting factor. In this project, the problem was encountered when using the yeast 
vector pESC-TRP which limited the insertion of genes to only two. The remaining genes 
must split into another vectors, which means that several rounds of transformation are 
required. Similar limitations also occurred in fungal-based systems; the fungal vector 
pTYGSarg, pTYGSade and pTYGSbar utilised in the study permitted the insertion up to 
three genes for each vector and at least three rounds of transformation were needed. Co-
transformation of two expression vectors might be a strategy to solve the problem. However, 
the result from this strategy could lead to the lower efficiency of the genes insertion when 
compare to the normal transformation procedure of one round one expression plasmid. The 
study from Alberti et al., (2017) showed that the efficiency of the insertion of transgenes 
from the transformation of one plasmid per round in A. oryzae range from 60% to 75%, while 
the result from co-transformation of two vectors decreased the efficiency of the insertion 
down to 20%.  
 
Apart from the challenge of the construction of the expression vector, the potential of the 
hosts to enhance pleuromutilin production was considered. According to the results from this 
project, yeast S. cerevisiae has been shown to be the most favourable platform for the 
development and pathway modification for the higher production of pleuromutilin, even 
though unexpected results were revealed from the chemical analysis of the yeast transformant 
strains. Within the time limit of this project, only preliminary approaches could be conducted 
in the yeast system. There are more investigations that should be done in this microbial 
platform. The successful cases of the metabolic engineering for the production of the 
intermediates of artemisinin and taxol as previously described in Chapter 5 could be used as a 
guideline for the metabolic engineering of pleuromutilin production. Furthermore, the study 
from Paddon et al., (2013) also reported the successful expression of the complete pathway 
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for artemisinic acid production. The S. cerevisiae strains were engineered for the higher 
production of artemisinic acid by optimising the expression ratio of CYP71AV1:CPR1 and 
combining with the expression of other three genes derived from A. annua (CYB5, ADH1 
and ALDH1), resulting in more than ten-fold increase of artemisinic acid titres or 25 g/L of 
the fermentation batch. In addition, they also developed the powerful, efficient and scalable 
chemical synthesis process in order to convert artemisinic acid to artemisinin. Compared to 
other methods they utilised singlet oxygen as a chemical source, screened several catalysts 
and provided the most efficient one into the reaction and also employed telescoping to the 
reactions to prevent any exhaustive of intermediates during purification and isolation. They 
have proved that by applying these chemical synthesis procedures with the 2 reactors of 
industrial batch reactor (5,000 – 10,000 L) resulted in the artemisinin production around 0.5-
1.0 tons per day. 
 
Plant-based systems provide effective heterologous expression especially for the production 
of valuable medicinal protein products. Factors that make plant systems favourable for 
recombinant protein production include: high value of pharmaceutical protein products, low-
cost biomass production compared with microbial fermentation, the potential for large-scale 
production using agriculture, the low risk contamination of products and no downstream 
process for protein purification is required for edible proteins produce in plant food (Doran, 
2006). The examples include an IgA/G antibody against oral streptococcal colonisation (Ma 
et al., 1998), an edible vaccine against an E. coli enterotoxin in transgenic potato (Tacket et 
al., 1998), an edible vaccine against hepatitis B in transgenic lupin and lettuce (Kapusta et al., 
1999). However, the metabolic engineering of plant for natural secondary metabolites 
production is still limited. The reasons might due to the structural complexity of the targeted 
compound, lack of knowledge of how to optimise the expression of heterologous genes, less 
understanding of expected metabolic networks within the native in planta biosynthesis, high 
competition of other metabolite pathways and desired compounds purification problem 
(Ikram et al., 2015). 
 
The well-established strategy to enhance the production of heterologous terpenoid 
compounds in plants refer to the cases of artemisinin biosynthesis and taxol biosynthesis. But 
it must be noted that those approaches include only a limited number of steps in biosynthesis. 
In both cases only partial heterologous expression of the genes involved in the pathway was 
successfully done. It is also the heterologous expression of plant genes to another plants. In 
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addition, the overall yield obtains from heterologous production resulting in the range of 
µg/L to mg/L from shake-flask culture. When considered the biosynthesis of pleuromutilin 
which involved multiple steps of enzymes activity and including the fact it is the 
heterologous production of the cross kingdom, so the metabolic engineering of pleuromutilin 
biosynthesis pathway will be more complicated and time-consuming to optimize in planta. 
However, the results from this project revealed the small trace of expected metabolite 2 from 
HPLC analysis. This might be suggested a hopeful possibility for further challenges to 
modify and develop the heterologous expression of pleuromutilin in planta. Furthermore, the 
result could be pinpointed as a stepstone for the heterologous expression of other fungal 
metabolites to be performed in planta.  
 
It is also worth noting that to synthesize a complex diterpene structure such as pleuromutilin, 
the expression of multiple CYP 450s are needed. Thus, to optimize the CYP 450s in order to 
fully function in the heterologous host, yeast and tobacco, is totally a challenging approach. 
These enzymes play a critical role for the pleuromutilin scaffold modification. Due to their 
nature as heme-containing enzymes, most CYP required its redox partner, cytochrome P450 
reductase (CPR), to transfer the electrons from NADPH for the activation of oxygen in the 
P450 catalytic cycle (Ikram et al., 2015, Xiao et al., 2019). Lack of electron transfer from 
CPR to CYP may result in the low activity of CYP, thus the CPR partner usually require for 
the heterologous expression along with CYP to support its activity (Xiao et al., 2019). 
Previous study from Zhang et al., (2011) reported that the heterologous expression of the 
three genes from A. annua, ADS, CYP71AV1 and DBR2 in tobacco results in the 
accumulation of dihydroartemisinic aldehyde but no artemisinic acid, the final intermediate 
of artemisinin pathway was detected. This result was not in agreement with the heterologous 
expression in yeast by Ro et al., (2006). The study from Ro et al., (2006), the heterologous 
expression of the genes derived from A. annua ADS, CYP71AV1 and its redox partner CPR, 
resulted in the production of 32 ± 13 mg/L artemisinic acid from liquid culture. The different 
results from these two studies suggest that the co-expression of CYP and its redox partner is 
significantly increase in its activity for further terpenoid structure modification.  
 
For this study A. oryzae seemed to be the less suitable heterologous host for pleuromutilin 
production. According to the attempts to overexpression the genes under a strong promoter, 
the results from this study showed no improvement in the functional expression of the genes. 
Even though, A. oryzae has the benefit in term of the ability to obtain high number copies of 
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expression vectors of the pleuromutilin biosynthesis gene cluster which could lead to higher 
titre of desired compounds. While yeast and plants would not be affected by the number of 
copies of the expression vectors. But many drawbacks such as the time-consuming 
techniques for the transformation and fermentation processes and instability of the 
transformant strains that could possibly happened during the strains selection, make this 
system not attractive for improving pleuromutilin production. 
Attempts for detection and purification of the intermediates from pleuromutilin biosynthesis 
pathway are the final step to investigate the improvement for pleuromutilin production. 
Within the three hosts, yeast might be the easiest system to manage for theses production 
processes. It offers a short time fermentation and including several steps for purification. 
Moreover, yeast mainly produce sterol, so there is less interference from the other secondary 
metabolite pathways. Whilst tobacco plants look like the most difficult system to purify 
compounds, the system is known to be a rich source of compounds and there are many native 
secondary metabolite pathways. Thus, metabolic engineering to decrease the interference 
from other competitive pathways and purify the desired compounds is seemed to be 
complicate procedures. The fungal host seems to have major disadvantages because of the 
time-consuming processes of strains construction until it reaches to the fermentation for mass 
production.  
As a conclusion, the results from this thesis have evaluated the potential of the three 
heterologous expression systems as rational platforms to enhance pleuromutilin production. It 
has also suggested a potential for the production of new compounds within the heterologous 
host. Yeast seems to be the most capable system for the metabolic engineering of 
pleuromutilin biosynthesis pathway. This because of its well-established platform and 
accessible knowledge for heterologous expression and a large-scale production from other 
terpenoids. Plant-based systems need to be carefully considered for the long-term project for 
the metabolic engineering until it could search the industrial scale and the obstacle of the 
purification process. Whilst the fungal host system seems to be the less attractive of hosts 
tested. The system faced the limitation for the improvement for the expression of the 
transgenes and the great drawback in term of time-consuming when compared to other 
systems. The outcomes from this study has demonstrated the potential to engineer 
heterologous hosts for improving the targeted pleuromutilin production and could be used as 
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a stepstone for the future attempts in order to develop metabolic engineering of pleuromutilin 
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